<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">101619</article-id>
<article-id pub-id-type="doi">10.7554/eLife.101619</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.101619.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Cancer Biology</subject>
</subj-group>
</article-categories>

<title-group>
<article-title>Multi-gradient Permutation Survival Analysis Identifies Mitosis and Immune Signatures Steadily Associated with Cancer Patient Prognosis</article-title>
</title-group>

<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0009-0005-4295-6371</contrib-id>
<name>
<surname>Cai</surname>
<given-names>Xinlei</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ye</surname>
<given-names>Yi</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3246-4227</contrib-id>
<name>
<surname>Liu</surname>
<given-names>Xiaoping</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fang</surname>
<given-names>Zhaoyuan</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Luonan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Fei</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<email>li_fei@fudan.edu.cn</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0891-6390</contrib-id>
<name>
<surname>Ji</surname>
<given-names>Hongbin</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a6">6</xref>
<email>hbji@sibcb.ac.cn</email>
</contrib>
<aff id="a1"><label>1</label><institution>Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences</institution>, Hangzhou, 310024, <country>China</country></aff>
<aff id="a2"><label>2</label><institution>State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences</institution>, Shanghai 200031, <country>China</country></aff>
<aff id="a3"><label>3</label><institution>Department of Pathology and Frontier Innovation Center, School of Basic Medical Sciences, Fudan University</institution>, Shanghai, <country>China</country></aff>
<aff id="a4"><label>4</label><institution>Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine</institution>, Haining, 314400, <country>China</country></aff>
<aff id="a5"><label>5</label><institution>The Second Affiliated Hospital, Zhejiang University School of Medicine</institution>, Hangzhou, 310000, <country>China</country></aff>
<aff id="a6"><label>6</label><institution>School of Life Science and Technology, Shanghai Tech University</institution>, Shanghai 200120, <country>China</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Archer</surname>
<given-names>Graeme</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>GlaxoSmithKline</institution>
</institution-wrap>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Ng</surname>
<given-names>Tony</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>King's College London</institution>
</institution-wrap>
<city>London</city>
<country>United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<pub-date date-type="original-publication" iso-8601-date="2024-10-31">
<day>31</day>
<month>10</month>
<year>2024</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP101619</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-08-27">
<day>27</day>
<month>08</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-08-27">
<day>27</day>
<month>08</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.02.20.581166"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Cai et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Cai et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-101619-v1.pdf"/>
<abstract>
<title>Abstract</title><p>The inconsistency of the association between genes and cancer prognosis is often attributed to many variables that contribute to patient survival. Whether there exist the Genes Steadily Associated with Prognosis (GEARs) and what their functions are remain largely elusive. We have developed a novel method called “Multi-gradient Permutation Survival Analysis” (MEMORY) to screen the GEARs using RNA-seq data from the TCGA database. Then we employed a network construction approach to identify hub genes from GEARs, and utilized them for cancer classification. In the case of LUAD, the GEARs were found to be related to mitosis. Our analysis suggested that LUAD cell lines carrying <italic>PIK3CA</italic> mutations exhibit increased drug resistance. For BRCA, the GEARs were related to immunity. The analysis revealed that <italic>CDH1</italic> mutation might influence immune infiltration through the EMT process in BRCA. We further explored the prognostic relevance of mitosis and immunity through their respective scores. This study offers significant biological insights into GEARs and highlights their potential as robust prognostic indicators across diverse cancer types.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Multi-gradient Permutation Survival Analysis (MEMORY)</kwd>
<kwd>Gene Steadily Associated with Prognosis (GEAR)</kwd>
<kwd>Hub Genes</kwd>
<kwd>Mitosis</kwd>
<kwd>Immune</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>We have further validated our findings through a serial of additional analyses. We have now investigated the correlation between hub gene subgroups and TNM staging, as well as explored the relationship between hub gene subgroups and prognosis within different LUAD subtypes. Additionally, we have delved into the applicability of MEMORY, which allows for standardizing patient background differences in a dataset and focus specifically on the impact of sample size on prognosis-related genes, albeit without the ability to integrate all clinical variables at this stage. Moreover, we have discovered that CDH1 mutation is linked to immune status in BRCA, offering a novel biological insight into cancer. We have now incorporated these new data into the revised Figure 3C-D and 6A-B, as well as the new supplementary Figures 5A-K, 6H-I and 7C-F. We believe that these revisions have significantly strengthened our conclusions.
</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Cancer is one of the leading causes of death worldwide, with over 200 types identified. Despite of huge advancements in the field, accurately predicting cancer patient prognosis still remains a significant challenge<sup><xref ref-type="bibr" rid="c1">1</xref>,<xref ref-type="bibr" rid="c2">2</xref></sup>. Previous studies have highlighted the complexity of this task, which is influenced by various factors including cancer type, clinical stage, therapeutic interventions, nursing care, unexpected comorbidities, and other non-cancer related illnesses that may interplay<sup><xref ref-type="bibr" rid="c3">3</xref>–<xref ref-type="bibr" rid="c6">6</xref></sup>. Furthermore, the gene expression plays a crucial role in predicting cancer patient prognosis, such as <italic>HER2</italic>, <italic>VEGF</italic>, <italic>Ki67</italic>, etc<sup><xref ref-type="bibr" rid="c7">7</xref>–<xref ref-type="bibr" rid="c12">12</xref></sup>. Nevertheless, there is still a need for further improvement in prognostic accuracy to better inform treatment decisions and patient outcomes.</p>
<p>Survival analysis is commonly used to assess the correlation between genes and cancer patient prognosis<sup><xref ref-type="bibr" rid="c13">13</xref></sup>. However, inconsistent findings are frequently observed, even within the same type of cancer. For instance, studies exploring the correlation between <italic>CCND1</italic> and prognosis in NSCLC reported contrasting results, including positive correlation, inverse correlation, or negligible influence<sup><xref ref-type="bibr" rid="c14">14</xref>–<xref ref-type="bibr" rid="c16">16</xref></sup>. These discrepancies can be attributed to various influential factors, such as differences in sample size, cohort characteristics (including cancer subtypes and tumor staging) and variations in therapy approaches<sup><xref ref-type="bibr" rid="c17">17</xref></sup>. Such observations raise an important question: whether there exist <underline>G</underline>enes St<underline>e</underline>adily <underline>A</underline>ssociated with Prognosis (GEARs) that consistently correlate with patient outcomes across different conditions, particularly considering the varying sample sizes used in different studies? Affirmative answers to this question would have significant implication not only for the development of more accurate prognostic models but also for enhancing our understanding of cancer biology.</p>
<p>The Cancer Genome Atlas (TCGA) is a comprehensive cancer genomics project initiated in the United States. It consists of transcriptome data, genomic data, and clinical information pertaining to 33 different cancer types, making it the largest cancer clinical sample database currently available. In this study, we developed a novel method called “<underline>M</underline>ulti-gradi<underline>e</underline>nt Per<underline>m</underline>utati<underline>o</underline>n Survival Anal<underline>y</underline>sis” (MEMORY) with the utilization of TCGA RNA-seq data, and accessed the potential existence of GEARs across 15 cancer types, each comprising a cohort of over 200 patients. Furthermore, we also evaluated the prognostic predictive power of these GEARs and explored their potential biological functions in driving cancer progression.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Multi-gradient permutation survival analysis identifies GEARs associated with mitosis and immune across multiple cancer types</title>
<p>GEARs are a group of genes consistently and significantly correlate with patient survival, independent of the sample size. To identify these GEARs, we developed a novel method called “<underline>M</underline>ulti-gradi<underline>e</underline>nt Per<underline>m</underline>utati<underline>o</underline>n Survival Anal<underline>y</underline>sis” (MEMORY). This method allows us to assess the correlation between a specific gene and cancer patient prognosis using available transcriptomic dataset (<xref rid="fig1" ref-type="fig">Figure 1A</xref>, <bold>Table 1</bold>). Initially, we started with a sampling number at 10% of the cohort size initially, and gradually increased the sampling number with each 10% increment, which was analyzed with 1000 permutations. By calculating the statistical probability of each gene’s association with patient survival, we can identify a group of GEARs for further analyses.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1:</label>
<caption><p>MEMORY uncovers the enrichment of mitosis and immune signatures in multiple cancers. (A) Sample sizes, ranging from 10% to 100% with 10% intervals (“gradient”), were used for 1000 permutations of survival analyses of all 15 cancer types Each matrix was divided into high and low expression groups based on median gene expression values, and survival analyses were performed. Log-rank test significance results were coded as 1 for significant (P &lt; 0.05) and 0 for non-significant (P &gt; 0.05) outcomes, forming survival analysis matrices and the summarized significant probability matrix, which allowed the identification of GEARs. (B) The maximum of significant probability for each gradient sample size of every cancer type. Sample number rate refers to the percentage of samples in each sampling gradient compared to the total number of samples. (C) The pathways were enriched by GOEA based on the GEARs of each cancer type. The displayed pathways represent the top 5 most significant pathways for each cancer type. Mitosis-related pathways were marked in red whereas immune-related pathways were marked in blue.</p></caption>
<graphic xlink:href="581166v2_fig1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>In this study, we utilized the TCGA datasets for several reasons, including the diversity of cancer types, the availability of gene expression profiles, and patient prognosis information. We set a minimum cohort size of 200 and included 15 eligible cancer types for analysis. These cancer types include bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical Adenocarcinoma (CESC), colon Adenocarcinoma (COAD), kidney renal papillary cell carcinoma (KIRC), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell sarcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and uterine corpus endometrial carcinoma (UCEC). As the number of samples increases, the survival probability of certain genes gradually approaches 1. Once this score reaches 0.8 and remained consistent with further sample gradient increase, the gene is considered a GEAR (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). Remarkably, we successfully identified a set of GEARs across all 15 cancer types (<bold>Supplementary Figure 1-2, Table 2</bold>). The GEAR counts in most cancer types ranged from 100 to1000, with exceptions of CESC, KIRC, LGG, and PAAD with over 1000 GEARs, and THCA with only 22 GEARS (<bold>Table 2</bold>). In LUAD, the top 10 GEARs with the highest significance probabilities were <italic>TLE1</italic>, <italic>GNG7</italic>, <italic>ERO1A</italic>, <italic>ANLN</italic>, <italic>DKK1</italic>, <italic>TMEM125</italic>, <italic>S100A16</italic>, <italic>KNL1</italic>, <italic>STEAP1</italic>, and <italic>BEX4</italic>. Most of these genes are known to promote LUAD malignant progression except for S100A16<sup><xref ref-type="bibr" rid="c18">18</xref>–<xref ref-type="bibr" rid="c26">26</xref></sup>. In other cancer types, <italic>BEX4</italic> was identified as a common GEAR in KIRC, LGG, PAAD, and STAD (Table 2). <italic>BEX4</italic> is reported as a proto-oncogene promoting cancer onset and malignant progression in multiple cancers including LUAD, glioblastoma multiforme and oral squamous cell carcinoma <sup><xref ref-type="bibr" rid="c25">25</xref>,<xref ref-type="bibr" rid="c27">27</xref>,<xref ref-type="bibr" rid="c28">28</xref></sup>. We also identified the most significant GEARs in individual cancer types, such as <italic>TLL1</italic> (BLCA), <italic>PGK1</italic> (BRCA), <italic>RFXANK</italic> (CESC), <italic>DPP7</italic> (COAD), <italic>VWA8</italic> (KIRC), <italic>SCMH1</italic> (LGG), <italic>HILPDA</italic> (LIHC), <italic>TLE1</italic> (LUAD), <italic>CD151</italic> (LUSC), <italic>ANKRD13A</italic> (OV), <italic>SOCS2</italic> (PAAD), <italic>DRG2</italic> (PRAD), <italic>ADAMTS6</italic> (STAD), <italic>PSMB8</italic> (THCA), <italic>ASS1</italic> (UCEC) (<bold>Table 3</bold>). Many of these genes were previously reported to associate with tumorigenesis<sup><xref ref-type="bibr" rid="c18">18</xref>,<xref ref-type="bibr" rid="c29">29</xref>–<xref ref-type="bibr" rid="c40">40</xref></sup>. For example, <italic>TLE1</italic> is known as a transcriptional repressor that promotes cell proliferation, migration, and inhibits apoptosis in LUAD <sup><xref ref-type="bibr" rid="c41">41</xref>,<xref ref-type="bibr" rid="c42">42</xref></sup>. Additionally, <italic>PGK1</italic>, a key enzyme in the glycolytic process, has been shown to promote cell proliferation, migration, and invasion in multiple cancers<sup><xref ref-type="bibr" rid="c43">43</xref>,<xref ref-type="bibr" rid="c44">44</xref></sup>. These findings demonstrate the intricate link between the functionality of GEARs and the initiation and progression of cancer.</p>
<p>To gain deep insights into the biological functions of these identified GEARs, we conducted Gene Ontology Enrichment Analysis (GOEA) (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). Interestingly, we found the mitosis-related pathways were enriched in LICH, LUAD, LGG, and PAAD, and the immune-related pathways were enriched in BRCA and UCEC<sup><xref ref-type="bibr" rid="c45">45</xref></sup>. Additionally, other cancer types exhibited enrichment in various pathways, such as organic acid metabolism pathway in KIRC, oxidative phosphorylation pathway in CESC, organ development-related pathways in LUSC, neurogenesis-related pathways in BLCA, and sustenance metabolism pathways in THCA. Given the crucial role of mitosis in cancer progression and the significance of the immune system in cancer-host interactions, we specifically focused on the mitosis and immune-related GERAs, which accounted for approximately 40% of all the analyzed cancers.</p>
</sec>
<sec id="s2b">
<title>Identification of hub genes in mitosis and immune-related cancers</title>
<p>To further identify crucial genes within the GEARs, we conducted and extracted the higher-ranked edges to construct the core survival network (CSN) (<xref rid="fig2" ref-type="fig">Figure 2A</xref>, <bold>Table 4</bold>). The top 10 GEARs with highest degree in these networks were defined as hub genes <sup><xref ref-type="bibr" rid="c46">46</xref></sup>. We then classified the samples using the hub genes derived from these networks and evaluated their clinical relevance (<bold>Supplementary</bold> Figure 3A-O<bold>, Supplementary</bold> Figure 4A-O). A certain degree of correlation with cancer stages (TNM stages) is observed in most cancer types except for COAD, LUSC and PRAD (<bold>Supplementary</bold> Figure 5A-K). Furthermore, we conducted GOEA on the hub genes selected from CSNs and found that the results were consistent with the GEAR analysis (<bold>Table 5</bold>). Specifically, the hub genes in LIHC, LGG, and LUAD were enriched in mitosis-related pathways, whereas the hub genes in BRCA and UCEC were enriched in immune-related pathways (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). For instance, the 9 hub genes in LUAD were associated with functions related to mitosis, whereas the 8 hub genes of BRCA were associated with immune-related functions (<xref rid="fig2" ref-type="fig">Figure 2C-D</xref>).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2:</label>
<caption><p>Identification of hub genes in mitosis or immune-related cancers. (A) The SAS of all GEARs was calculated, and CSN was constructed. (B) The left nodes represent five different cancers, while the right nodes detail the functional types of hub-gene pathways. The height of the edges in the middle represents the proportion of hub-gene pathways corresponding to a specified functional type. (C-D) The CSN of LUAD and BRCA. The enlarged section represents the hub gene. (E) LUAD clustering based on hub gene expression, compared with inhibitor-based classification<sup><xref ref-type="bibr" rid="c52">52</xref></sup>. (F-G) LUAD clustering based on hub gene expression in comparison with the classic classification.</p></caption>
<graphic xlink:href="581166v2_fig2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Furthermore, we conducted survival-dependent analyses on the hub genes of LGG, LIHC, and LUAD. These analyses revealed that mitosis-related hub genes are closely associated with cancer cell viability, especially those hub genes that are correlated with multiple cancer types such as <italic>CDC20</italic>, <italic>TOP2A</italic>, <italic>BIRC5</italic> and <italic>TPX2</italic><sup><xref ref-type="bibr" rid="c47">47</xref>–<xref ref-type="bibr" rid="c50">50</xref></sup> (<bold>Supplementary</bold> Figure 6A-C). The importance of these genes is well established. For instance, <italic>TPX2</italic>, a hub gene in all three cancers, is known to play a crucial role in normal spindle assembly during mitosis and is essential for cell proliferation<sup><xref ref-type="bibr" rid="c51">51</xref></sup>. The significance of these hub genes for the survival of cancer cells suggests that the expression levels of these hub genes can be used to screen for inhibitors of tumor cell growth. By integrating the Genomics of Drug Sensitivity in Cancer (GDSC) and Connectivity Map (cMAP) databases, we identified 76 individual compounds that are able to effectively suppress the expression of the 10 hub genes in LUAD cell lines (<xref rid="fig2" ref-type="fig">Figure 2E</xref><bold>, Supplementary</bold> Figure 6D-E). These compounds also significantly inhibit LUAD cell growth and may serve as potential therapeutic agents for the treatment of LUAD.</p>
<p>We then analyzed the LUAD dataset, which had a larger sample size compared to LGG and LIHC. Based on the expression of the hub genes, we classified the LUAD samples into three subgroups: mitosis low (ML), mitosis medium (MM), and mitosis high (MH) (<xref rid="fig2" ref-type="fig">Figure 2F</xref>, <bold>Table 6</bold>). Previous study has reported three classic subgroups of LUAD known as the terminal respiratory unit (TRU), the proximal-proliferative (PP), and the proximal-inflammatory (PI) subgroups<sup><xref ref-type="bibr" rid="c52">52</xref></sup>. Our analysis revealed that the ML subgroup was primarily enriched with TRU subgroup and a small number of samples from the PP subgroup, but not the PI subgroup. The MH subgroup showed high expression of mitosis-related genes and predominantly encompassed PI and PP subgroups, whereas the MM group exhibited intermediate levels of mitosis-related gene expression (<xref rid="fig2" ref-type="fig">Figure 2F-G</xref>). This suggests that the new categorization method can help identify new factors that influence patient prognosis (<bold>Supplementary</bold> Figure 6F-G).</p>
</sec>
<sec id="s2c">
<title>Distinct genetic mutation landscapes characterize different clusters of LUAD</title>
<p>The expression of hub genes provided crucial indicators for distinguishing various subgroups of LUAD. However, the underlying mechanisms driving these variations in expression patterns remain unknown. In our subsequent research, we aimed to explore the genomic differences, particularly in terms of gene mutations, among different LUAD subgroups. Initially, we analyzed the variations of genetic mutation landscape of different LUAD subgroups by assessing the tumor mutation burden (TMB). Interestingly, we found significant differences in TMB among the various subgroups of LUAD (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). Analysis of common driver genes further revealed distinct proportions of tumors with <italic>ALK</italic> and <italic>ROS1</italic> fusions in the favorable prognosis ML and MM subgroups, compared to tumors with mutations in <italic>KRAS</italic>, <italic>EGFR</italic>, <italic>BRAF</italic>, and <italic>ERBB2</italic> (<xref rid="fig3" ref-type="fig">Figure 3B</xref>). Moreover, low tumor mitotic activity is associated with better prognosis in LUAD subgroups with <italic>EGFR</italic> mutations or pan-negative (no oncogenic alteration in genes including <italic>KRAS</italic>, <italic>EGFR</italic>, <italic>BRAF</italic>, <italic>ERBB2</italic>, <italic>PIK3CA</italic>, <italic>ALK</italic> and <italic>ROS1</italic>) but not in those with <italic>KRAS</italic> or <italic>BRAF</italic> mutations (<xref rid="fig3" ref-type="fig">Figure 3C-D</xref><bold>, Supplementary</bold> Figure 6H-J). Furthermore, we observed unique mutation characteristics in each of these 3 subgroups (<xref rid="fig3" ref-type="fig">Figure 3E-G</xref>). For example, TP53 mutation, a prevalent tumor suppressor gene mutation, was frequently observed in the MH subgroup with a mutation rate of 73%, compared to mutation rates of 14% in the ML subgroup and 39% in the MM subgroup. Additionally, genes such as <italic>CSMD3</italic>, <italic>RP1L1</italic>, <italic>ZFHX4</italic> exhibited similar trend in mutation frequency across the three subgroups. These findings indicate substantial genomic differences among these three LUAD subgroups based on the hub genes.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3:</label>
<caption><p>Different LUAD subgroups were characterized by unique genetic mutation profiles. (A) TMB analysis in three groups of LUAD samples. ***P &lt; 0.0005. (B) Proportion of different oncogenic drivers including <italic>KRAS</italic>, <italic>EGFR</italic>, <italic>BRAF</italic>, <italic>ERBB2</italic> mutations, and <italic>ALK</italic>, <italic>ROS1</italic> fusions in three LUAD subgroups. (C) Kaplan-Meyer overall survival curves for EGFR-mutation samples of LUAD by hub gene subgroups. (D) Kaplan-Meyer overall survival curves for pan-negative LUAD samples by hub gene subgroups. (E-G) Comparison of top gene mutations in three LUAD clusters, including ML vs. MM (C), MM vs. MH (D), ML vs MH (E).</p></caption>
<graphic xlink:href="581166v2_fig3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>We identified gene mutations that showed significant changes through gene dependence analysis (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). To further the functional implications of these mutations, we enriched them using a pathway system called Nested Systems in Tumors (NeST)<sup><xref ref-type="bibr" rid="c53">53</xref></sup>. The results revealed notable differences in multiple functional pathways, including androgen receptor, cell cycle, <italic>TP53</italic>, <italic>EGFR</italic>, IL-6, and <italic>PIK3CA</italic>-related pathways (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). To gain further insights into the functional implications of these different mutations, we assessed the gene dependency of cells with these mutations using the DepMap database. Importantly, we observed that the pathway differences between the MM and MH clusters were primarily associated with <italic>PIK3CA</italic>-related pathways. Previous studies have reported that <italic>PIK3CA</italic> mutation confers resistance in colorectal cancer, lung cancer, and breast cancer<sup><xref ref-type="bibr" rid="c54">54</xref>–<xref ref-type="bibr" rid="c56">56</xref></sup>. Therefore, we aimed to validate the role of <italic>PIK3CA</italic> mutations in drug resistance using public databases. We further analyzed A549 cells (a lung adenocarcinoma cell line with <italic>KRAS</italic> mutation) and SW1573 cells (a lung adenocarcinoma cell line with both <italic>KRAS</italic> and <italic>PIK3CA</italic> mutations) using their respective GDSC data and identified five potentially effective inhibitors (BMS-345541, Dactinomycin, Epirubicin, Irinotecan, and Topotecan) from the previously screened set of 76 LUAD cell growth inhibitors. Strikingly, SW1573 cells exhibited increased resistance to all these 5 inhibitors when compared to A549 cells (<xref rid="fig4" ref-type="fig">Figure 4C</xref>). In line with this, clinical data also supports the notion that concurrent <italic>PIK3CA</italic> mutation is a poor prognostic factor for LUAD patients<sup><xref ref-type="bibr" rid="c57">57</xref></sup>. These findings suggest that <italic>PIK3CA</italic> mutation may contribute to drug resistance in LUAD.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4:</label>
<caption><p>PIK3CA mutation associates with mitosis and drug resistance in LUAD. (A) Cancer-related gene mutations were annotated based on gene dependency scores data from Depmap database. Functional mutations were indicated in green; functional (subtype-associated) mutations were highlighted in red; non-functional mutations were indicated in gray. (B) The analysis of the NeST differential pathways across three groups including ML vs. MM, MM vs. MH, ML vs MH. (C) The heat map showed the hub gene expression of A549 after compounds treatment from cMAP database<sup><xref ref-type="bibr" rid="c98">98</xref></sup>. Blue annotations meant 76 compounds that can inhibit hub gene expression. (D) Comparison of the IC50 z-score of five tumor cell growth inhibitors for A549 (<italic>KRAS</italic> mutation) and SW1573 (<italic>KRAS</italic> and <italic>PIK3CA</italic> mutation).</p></caption>
<graphic xlink:href="581166v2_fig4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2d">
<title>Distinct clusters of BRCA exhibit different immune infiltration landscapes</title>
<p>We further focused on the immune-related cancer types, with BRCA standing out as a representative immune-related cancer. This prompted us to conduct a more comprehensive analysis (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). We hierarchically grouped the BRCA into three distinct immune subgroups based on the expression of hub genes: Immune low (IL), Immune medium (IM), and Immune high (IH) (<xref rid="fig5" ref-type="fig">Figure 5A</xref>, <bold>Table 7</bold>). Interestingly, all the classifications based on the widely used PAM50 classification contained samples from the IL, IM, and IH subgroups, although there were minor differences in proportions<sup><xref ref-type="bibr" rid="c58">58</xref></sup> (<xref rid="fig5" ref-type="fig">Figure 5B</xref><bold>, Supplementary</bold> Figure 7A-B). Next, we investigated the relationship among PAM50 classification, immune subtypes, and patient prognosis. Our data revealed significant prognostic differences among immune subgroups of the LumB subtypes but not the LumA, Basal or Her2 subtype (<bold>Supplementary</bold> Figure 7C-F). Integrating our method with traditional classification may enable a more detailed stratification of breast cancer samples. Mutation analysis revealed distinct patterns of gene mutations among the three subgroups, with significant differences in mutation frequencies of genes such as <italic>TP53</italic>, <italic>CDH1</italic>, and <italic>LRP2</italic> (<xref rid="fig5" ref-type="fig">Figure 5C-E</xref>). We conducted a comparison of the proportions of immune cells across these three subgroups and observed a strong association between the overall immune cell proportion and the clustering results based on hub genes (<xref rid="fig5" ref-type="fig">Figure 5F</xref><bold>, Supplementary</bold> Figure 8A-J). Specifically, the IH subgroup exhibited significantly higher proportions of CD8<sup>+</sup> T cells and Treg cells, with mean percentages at 5.0% and 6.0%, respectively, compared to 1.4% and 3.2% in the IM subgroup, and 0.3% and 1.6% in the IL subgroup. These findings suggest the presence of distinct immune responses in these three subgroups, indicating a potential association between genetic mutation pattern and the immune microenvironment landscape.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5:</label>
<caption><p>The hub gene classification of BRCA revealed a significant association between EMT and immune infiltration. (A) The hub gene expression heatmap containing the result of hub gene classification and PAM50 classification of BRCA<sup><xref ref-type="bibr" rid="c58">58</xref></sup>. (B) Comparison of molecular classification based on hub genes with PAM50 classification. (C-E) Comparison of gene mutations in three groups of BRCA samples, including IL vs. IM (C), IM vs. IH (D), IL vs. IH (E). (F) Comparison of the total immune cell rate in three BRCA clusters. ***P &lt; 0.0005. (G) Comparison of <italic>CDH1</italic> expression in BRCA samples with wildtype or mutant <italic>CDH1</italic>. ***P &lt; 0.0005. (H) A schematic diagram illustrating the correlation between the EMT score and immune cell rate. The red line represents the fitting curve. The correlation analysis was performed using Pearson correlation coefficient.</p></caption>
<graphic xlink:href="581166v2_fig5.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Next, we explored the specific genomic factors influencing immune infiltration in BRCA. Mutation analysis revealed that <italic>CDH1</italic> gene mutation ranked as the second most prevalent genetic alteration in BRCA samples, following TP53 mutation (<xref rid="fig5" ref-type="fig">Figure 5C-E</xref>). Previous study has indicated that <italic>CDH1</italic> is involved in mechanisms regulating cell-cell adhesions, mobility, and proliferation of epithelial cells<sup><xref ref-type="bibr" rid="c59">59</xref></sup>. We found that <italic>CDH1</italic>-mutant samples exhibited significantly lower <italic>CDH1</italic> expression compared to <italic>CDH1-</italic>wildtype samples, and <italic>CDH1</italic> expression showed a close correlation with immune cell infiltration (<xref rid="fig5" ref-type="fig">Figure 5G</xref><bold>, Supplementary</bold> Figure 8K). These results were consistent with clinical observations of <italic>CDH1</italic> mutation and high immune infiltration in invasive lobular carcinoma of the breast <sup><xref ref-type="bibr" rid="c60">60</xref></sup>.</p>
<p>We further investigated how <italic>CDH1</italic> mutation influenced immune infiltration. In BRCA, we observed a significant association between the expression of <italic>CDH1</italic> and the expression of EMT marker genes <italic>VIM</italic> and <italic>TWIST2</italic> (<bold>Supplementary</bold> Figure 8L-M)<sup><xref ref-type="bibr" rid="c61">61</xref>,<xref ref-type="bibr" rid="c62">62</xref></sup>. This suggests that the regulation of <italic>CDH1</italic> is intricately linked with EMT process. Through calculating the EMT score, we observed a positive correlation between the EMT score and the proportion of immune infiltration (<xref rid="fig5" ref-type="fig">Figure 5H</xref>). Consequently, <italic>CDH1</italic> might influence immune infiltration through the EMT process.</p>
</sec>
<sec id="s2e">
<title>Mitotic and immune signatures predict patient prognosis at pan-cancer level</title>
<p>We further analyzed the association of <italic>CDH1</italic> and <italic>PIK3CA</italic> with specific biological processes at pan-cancer level. Our data showed that <italic>PIK3CA</italic> level was positively correlated with mitotic scores in most cancer types, whereas the correlation between <italic>CDH1</italic> expression and the proportion of immune cell infiltration was positive in PRAD, LGG, OV, Uveal Melanoma (UVM), THCA, LIHC and LUAD but negative in BRCA, Testicular Germ Cell Tumors (TGCT), Thymoma (THYM), LUSC, BLCA, Head and Neck squamous cell carcinoma (HNSC), Sarcoma (SARC), Esophageal carcinoma (ESCA), PAAD and STAD (<xref rid="fig6" ref-type="fig">Figure 6A-B</xref>). Finally, we sought to explore the prognostic relevance of mitosis and immune by calculating their scores and assessing their correlation with patient outcomes at the pan-cancer level. The scores for these biological processes were computed using RNA-seq data from the TCGA database, and the median score was used as a cut-off to categorize patients into different groups. Out of the 33 cancer types analyzed, the prognosis of 19 cancer types showed a significant correlation with at least one of these two pathways (<xref rid="fig6" ref-type="fig">Figure 6C</xref>). Specifically, 10 cancer types were exclusively associated with the mitosis score, 4 cancer types were exclusively associated with the immune score, and 5 cancer types exhibited a correlation with both mitosis and immune scores simultaneously. Overall, the identification of mitosis and immune-related biological processes as significant prognostic factors at the pan-cancer level suggests their potential utility as valuable biomarkers for predicting patient prognosis.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6:</label>
<caption><p>Mitosis and immune signatures predict patient prognosis at the pan-cancer level. (A) The correlation of mitosis scores of 33 TCGA cancer types with <italic>PIK3CA</italic> expression was analyzed. (B) The correlation of immune cell infiltration rate of 33 TCGA cancer types with <italic>CDH1</italic> expression was analyzed. (C) The mitosis and immune-related pathway scores of 33 cancer types were analyzed, and the median score was utilized as a threshold to categorize patients for survival analysis. Among the 33 cancer types examined, 10 cancer types were exclusively associated with the mitosis score, 2 cancer types were exclusively associated with the immune score, and 5 cancer types showed a correlation with both mitosis and immunity scores concurrently.</p></caption>
<graphic xlink:href="581166v2_fig6.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Due to the multifaceted nature of variables affecting cancer patient prognosis, it remains uncertain whether there exist a set of genes steadily associated with cancer prognosis, regardless of sample size and other factors. Here, we utilized the MEMORY method to address this question and discovered that all the cancer types have GEARs. We observed significant variation in the number of GEARs among different cancer types, indicative of cancer type-specific patterns. The substantial heterogeneity in driver gene and mortality rates among various cancer types could potentially explain this phenomenon. For example, THCA, known for its low malignancy, displays the fewest genetic expression alterations among all the studied cancer types. This observation could be correlated with the relatively high five-year survival rate in THCA, which exceeds 50% even in advanced stage<sup><xref ref-type="bibr" rid="c63">63</xref></sup>. In contrast, PRAD, despite of a favorable prognosis similar to THCA, exhibits a significantly higher number of genetic expression alterations. We hypothesize that the positive prognosis in PRAD cases might be largely attributed to early diagnosis, which enables timely treatment for the majority of PRAD patients<sup><xref ref-type="bibr" rid="c64">64</xref></sup>. This discrepancy between the number of genetic alterations and prognosis in THCA and PRAD highlights the intricate nature of cancer genetics and emphasizes the importance of personalized considerations in cancer treatment and prognosis evaluation. Furthermore, certain genes are commonly found in the GEARs of various cancer types, indicating their potential significance in cancer development. For instance, <italic>BEX4</italic> is present in the GEARs of LUAD, KIRC, LGG, PAAD, and STAD, and known to play oncogenic role in inducing carcinogenic aneuploid transformation via modulating the acetylation of α-tubulin<sup><xref ref-type="bibr" rid="c65">65</xref>,<xref ref-type="bibr" rid="c66">66</xref></sup>. Aneuploidy is a hallmark characteristic of cancer and can lead to alterations in the dosage of oncogenes or tumor suppressor genes, thereby influencing tumor initiation and progression <sup><xref ref-type="bibr" rid="c67">67</xref>–<xref ref-type="bibr" rid="c70">70</xref></sup>. The regulation of aneuploid transformation by <italic>BEX4</italic> may represent a common mechanism through which this gene impacts prognosis across different cancer types. Subsequently, we discovered that GEARs across different cancers displayed distinct functional characteristics. Notably, a recurrent theme was the prominence of mitosis-related and immune-related features. Specifically, the GEARs of LGG, LIHC, and LUAD were enriched in mitosis-related pathways, whereas BRCA and UCEC showed the enrichment of immune-related pathways. Mitosis and immune processes have been widely recognized as having a significant impact on patient prognosis<sup><xref ref-type="bibr" rid="c71">71</xref>–<xref ref-type="bibr" rid="c75">75</xref></sup>. However, current clinical guidelines do not yet recommend the use of transcriptomic data to assess scores related to mitotic and immune pathways for predicting patient outcomes, despite the well-established association between these pathways and prognosis in cancer<sup><xref ref-type="bibr" rid="c76">76</xref>–<xref ref-type="bibr" rid="c81">81</xref></sup>. Cancers enriched with mitosis pathways often exhibit heterogeneous tumor growth kinetics across individuals, with tumor size being one of the crucial factors influencing patient survival <sup><xref ref-type="bibr" rid="c82">82</xref>–<xref ref-type="bibr" rid="c84">84</xref></sup>. For instance, in the case of LGG, the growth rate of tumors directly impacts the patient’s prognosis due to the primary location in the brain. Consequently, alterations in the expression levels of genes related to mitosis are often indicative of the prognosis of LGG <sup><xref ref-type="bibr" rid="c85">85</xref></sup>. Cancer types that are enriched in immune-related pathways, such as BRCA and UCEC, are closely associated with deficiencies in DNA mismatch repair (MMR) <sup><xref ref-type="bibr" rid="c86">86</xref>,<xref ref-type="bibr" rid="c87">87</xref></sup>. Cancers enriched in immune-related pathways often exhibit heterogeneous tumor growth kinetics across individuals, where tumor size is closely correlated with patient survival.</p>
<p>To explore the underlying differences between samples associated with distinct mitotic and immune-related pathways, we employed GEAR analysis to identify hub genes for further molecular classification and mutation analysis. Specifically, we focused on LUAD and BRCA, two representative cancer types exhibiting enriched mitosis and immune signatures in GEARs. By classifying the hub gene, we divided LUAD into three subgroups: ML, MM and MH, which displayed significant difference in survival outcomes. Subsequently, we utilized NeST to analyze the mutations within these subgroups. Notably, there were significant differences observed in cell cycle and signal transduction-related pathways among ML, MM and MH subgroups. Of particular importance, the <italic>PIK3CA</italic>-related pathway emerged as a key differentiating pathway between the MH and MM subgroups. Our analyses suggest that LUAD cell line carrying <italic>PIK3CA</italic> mutation may exhibit increased drug resistance. This aligns with previous studies demonstrating that targeting the PI3K pathway can overcome drug resistance<sup><xref ref-type="bibr" rid="c88">88</xref>,<xref ref-type="bibr" rid="c89">89</xref></sup>. Of course, future research is warranted to elucidate the exact functional role of <italic>PIK3CA</italic> mutations in LUAD.</p>
<p>To investigate the factors influencing immune infiltration in BRCA, we classified the samples based on hub genes and analyzed the differentially mutated genes. Interestingly, we found that <italic>CDH1</italic> mutation occurred at a high frequency in the IH subgroups. This led us to speculate that <italic>CDH1</italic> plays a crucial role in the regulation of immune infiltration in BRCA. Furthermore, previous studies have reported that <italic>CDH1</italic> inactivation promotes immune infiltration in breast cancer<sup><xref ref-type="bibr" rid="c60">60</xref></sup>. <italic>CDH1</italic> is a vital gene associated with EMT, and various studies have demonstrated the close relationship between EMT and the tumor immune microenvironment in different cancers<sup><xref ref-type="bibr" rid="c90">90</xref></sup>. Consistently, our results also supported the correlation between EMT score and immune infiltration in BRCA. These findings suggest that the mutations in <italic>PIK3CA</italic> and <italic>CDH1</italic>, identified through GEAR analysis, have significant impacts on cancer development and hold potential value in improving clinical therapies. This further emphasizes the importance of GEARs in understanding cancer biology and guiding treatment strategies.</p>
<p>Lastly, we investigated the prognostic predictive capabilities of the mitosis score and immune score at the pan-cancer level. Surprisingly, we found that approximately half of the cancer types exhibited significant correlations between these two scores and patient prognosis. Interestingly, even for cancers originating from the same primary location, their correlations with these scores could differ, indicating the potential diversity of mechanisms underlying cancer-related mortality. For instance, both LGG and GBM are brain tumors, but the primary risk factor for patient prognosis in LGG is closely linked to tumor diameter, whereas the main risk factor for GBM patients lies in its high invasiveness and challenge of surgical resection<sup><xref ref-type="bibr" rid="c91">91</xref>,<xref ref-type="bibr" rid="c92">92</xref></sup>.</p>
<p>Despite of the strong association between GEAR and patient prognosis, the edges of the CSN constructed based on GEARs was undirected. As a result, the hub genes identified from GEAR in the CSN may primarily serve as stable and effective biological markers. Additionally, through multi-omics analysis, we obtained some functional mutations, but the therapeutic significance of these mutations remains to be elucidated. For example, further study is needed to understand the exact role of <italic>PIK3CA</italic> mutations in promoting tumor cell proliferation and drug resistance. Similarly, the association of <italic>CDH1</italic> mutations with the infiltration of multiple immune cell types also warrants additional experimental investigation. In our future studies, we plan to utilize protein-protein interaction networks and pathway databases to construct a novel network based on the CSN. This approach will allow us to directly screen genes from GEARs that could potentially serve as therapeutic targets. Undoubtedly, future efforts are still required to utilize protein-protein interaction networks and pathway databases to construct a new network based on CSN.</p>
<p>In conclusion, our study utilized the MEMORY algorithm to identify GEARs in 15 cancer types, highlighting the significance of mitosis and immunity in cancer prognosis. Our findings demonstrate that GEARs possess substantial biological significance beyond their role as prognostic biomarkers. This study provides valuable guidance for establishing standards for survival analysis evaluation and holds potential for the development of novel therapeutic strategies.</p>
</sec>
<sec id="s4">
<title>Methods</title>
<sec id="s4a">
<title>Datasets</title>
<p>The gene expression profiles and clinical information of 33 cancers were obtained from the TCGA database and downloaded by the GDC data website (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>). All gene expression data and survival data were integrated and normalized.</p>
</sec>
<sec id="s4b">
<title>Multi-gradient permutation survival analysis</title>
<p>Gene expression data of cancer patients were obtained from the RNA-seq expression matrix of TCGA after TPM normalization. We randomly sampled the gene expression data according to the gradient. The sampling strategy was as follows: Ten gradient increases in sample size were pre-set, ranging from approximately 10% to about 100%, with intervals of 10%. Random samples were taken from total samples of each cancer 1000 times, based on each pre-set sample size. Multiple sampling matrix was obtained after the sampling strategy was performed in each gradient. The survival analysis was performed for every sampling matrix by “survival” and “survminer”. “survival” and “survminer” are R packages for survival analysis. The survival analysis method was as follows according to the median expression value of every gene, every sampling matrix was divided into a high and low expression group and performed survival analysis by “survival” and “survminer”. We used 1 for significant survival analysis results (P &lt; 0.05) and 0 for non-significant results (P &gt; 0.05). The survival analysis matrices were obtained after these processes.</p>
</sec>
<sec id="s4c">
<title>Construction of core survival network</title>
<p>The survival analysis matrices were integrated to a significant-probability matrix by a formula:
<disp-formula id="eqn1">
<graphic xlink:href="581166v2_eqn1.gif" mime-subtype="gif" mimetype="image"/>
</disp-formula>
where the <italic>A<sub>ij</sub></italic> is the value from row <italic>i</italic> and column <italic>j</italic> in the significant-probability matrix. We defined the sampling size <italic>k<sub>j</sub></italic> reached saturation when the max value of column j was equal to 1 in a significant-probability matrix. The least value of <italic>k<sub>j</sub></italic> was selected, and the genes with their corresponding <italic>A<sub>ij</sub></italic> greater than 0.8 were extracted as GEAR.</p>
<p>We also defined survival analysis similarity (<italic>SAS</italic>) as the similarity of the effect on patient prognosis in two genes. The <italic>SAS</italic> computational formula is as follows:
<disp-formula id="eqn2">
<graphic xlink:href="581166v2_eqn2.gif" mime-subtype="gif" mimetype="image"/>
</disp-formula>
</p>
<p>Where <italic>A</italic> and <italic>B</italic> are results of <italic>1000</italic> survival analyses at the first sampling gradient, which are sequences of <italic>0</italic> and <italic>1</italic> of length <italic>1000</italic>. <italic>A</italic> ∩ <italic>B</italic> means the number of events that are simultaneously 1 in both A and B. <italic>A</italic> ∪ <italic>B</italic> means the size of the union of <italic>A</italic> and <italic>B</italic>. The <italic>SAS</italic> of significant genes with total genes was calculated, and the significant survival network was constructed. Then some <italic>SAS</italic> values at the top of the rankings were extracted, and the <italic>SAS</italic> was visualized to a network by Cytoscape<sup><xref ref-type="bibr" rid="c93">93</xref></sup>. The network was named core survival network (CSN). The degree of each node was calculated, and the nodes with the top10 degrees were defined hub genes. The effect of molecular classification by hub genes is indicated that 1000 to 2000 was a range that the result of molecular classification was best. One thousand was chosen as the number of <italic>SAS</italic>. Therefore, one thousand was selected as the number of <italic>SAS</italic> values for constructed significant survival network.</p>
</sec>
<sec id="s4d">
<title>Gene ontology enrichment analysis</title>
<p>Gene ontology has been used to classify genes based on functions. The gene functions were divided three types, includes molecular function (MF), biological process (BP), and cellular component (CC). ClusterProfiler is an R package for gene set enrichment analysis<sup><xref ref-type="bibr" rid="c94">94</xref></sup>. The gene ontology enrichment analysis (GOEA) was processed in significant gene sets and hub genes by ClusterProfiler.</p>
</sec>
<sec id="s4e">
<title>Hub gene classification</title>
<p>Tumor samples were genotyped using RNA-seq data. The following steps outline the genotyping and clustering methods used in this study. The expression matrix of hub genes corresponding to various cancer types was extracted from the RNA-seq data. This involved filtering the RNA-seq data to retain only the expression levels of the identified hub genes. To normalize the expression data and reduce the impact of extreme values, a pseudo count of 1 was added to each expression value, and the resulting matrix <italic>M</italic> was log-transformed using the formula: <italic>M</italic><sup>′</sup> = <italic>log</italic><sub>2</sub>(<italic>M</italic> + 1). The log-transformed matrix <italic>M</italic><sup>′</sup> was then subjected to hierarchical clustering. This clustering was performed using the Ward’s method to minimize the variance within clusters. The distance metric used was the Euclidean distance. The number of clusters was determined based on the dendrogram cut-off.</p>
</sec>
<sec id="s4f">
<title>Calculation of tumor mutation burden (TMB) and differential mutation</title>
<p>The TMB and differential mutation gene analysis were carried out to explore the differences between different genotyped samples at the genomic level. The data are from the gene mutation data of TCGA tumor samples, and the grouping information is from the hub gene hierarchical clustering results. Maftools is an R package for the analysis of somatic variant data, which can export results in form of charts and graph<sup><xref ref-type="bibr" rid="c95">95</xref></sup>. The calculation of TMB and difference mutation analysis were used by the maftools.</p>
</sec>
<sec id="s4g">
<title>Quantifying the effect of gene mutations for tumor cell viability</title>
<p>Gene dependence refers to the extent to which genes are essential for cell proliferation and survival. The Cancer Dependency Map (Depmap, <ext-link ext-link-type="uri" xlink:href="https://depmap.org/portal/">https://depmap.org/portal/</ext-link>) database provides genome-wide gene dependence data for large number of tumor cell lines<sup><xref ref-type="bibr" rid="c96">96</xref></sup>. Gene mutation data of cell lines were obtained from the CCLE database (<ext-link ext-link-type="uri" xlink:href="https://sites.broadinstitute.org/ccle">https://sites.broadinstitute.org/ccle</ext-link>). The genes appearing in the gene mutation data of cell lines were extracted and sorted into mutation list. Each gene in the list was then analyzed for survival-dependent differences. For each gene in the mutation list, we compared the gene dependence score (<italic>S</italic>) between cell lines with and without the gene mutation. Specifically, cell lines from the CCLE mutation dataset harboring a mutation in a given gene were classified into one group, while cell lines without the mutation constituted the control group. <italic>S</italic> for the mutation (<italic>S<sub>m</sub></italic>) and wild-type (<italic>S<sub>wt</sub></italic>) cell lines were then extracted from the DepMap database.</p>
<p>A two-sample t-test was used to assess the statistical significance of differences between <italic>S<sub>m</sub></italic> and <italic>S<sub>wt</sub></italic>. The test yielded a P-value, with an alpha level set at 0.05, to determine the significance of the difference in means. <italic>D<sub>m</sub></italic> was defined as gene mutation dependence, the computational formula was as follows:
<disp-formula id="eqn3">
<graphic xlink:href="581166v2_eqn3.gif" mime-subtype="gif" mimetype="image"/>
</disp-formula>
</p>
<p>Subsequently, we conducted a standardization assessment of <italic>D<sub>m</sub></italic>, employing the following formula:
<disp-formula id="eqn4">
<graphic xlink:href="581166v2_eqn4.gif" mime-subtype="gif" mimetype="image"/>
</disp-formula>
</p>
<p>In this study, we categorized mutations identified in cell lines into three groups based on their impact on gene dependency. Functional mutations refer to the mutations that exhibit significant changes in gene dependency scores, with a P-value &lt; 0.05 and <italic>S<sub>dm</sub></italic> &gt; 0.1. Non-functional mutations were those without significant changes in gene dependency scores compared to wildtype. Subtype-associated functional mutations were a subset of functional mutations that show statistically significant differences in occurrence frequency across different LUAD subtypes.</p>
</sec>
<sec id="s4h">
<title>Identification of drugs downregulating hub gene expression</title>
<p>The IC50 data of 76 compounds of LUAD cell lines were obtained from Genomics of Drug Sensitivity in Cancer (GDSC) database<sup><xref ref-type="bibr" rid="c97">97</xref></sup>. The hub gene expression data of A549 cell lines after treatment with 76 compounds was obtained from Connectivity MAP (cMAP, <ext-link ext-link-type="uri" xlink:href="https://clue.io/">https://clue.io/</ext-link>) database, and the data were grouped by hierarchical clustering<sup><xref ref-type="bibr" rid="c98">98</xref></sup>. The drugs which were presented only in the hub gene expression suppression group were considered to effective against the LUAD cell.</p>
</sec>
<sec id="s4i">
<title>Immune infiltration analysis</title>
<p>Immune infiltration data was calculated by quantiseq method<sup><xref ref-type="bibr" rid="c99">99</xref></sup>. Immunedeconv was an R package for unified access to computational methods for estimating immune Cell fractions from bulk RNA-seq data<sup><xref ref-type="bibr" rid="c100">100</xref></sup>. The data were from the gene expression data of TCGA tumor samples after TPM was standardized. Then the immune cell fractions of tumor samples were calculated by quantiseq method invoking immunedeconv.</p>
</sec>
<sec id="s4j">
<title>Biological function score calculation</title>
<p>GSVA is an R package for calculate biological function score based on a single sample<sup><xref ref-type="bibr" rid="c101">101</xref></sup>. The data was from TCGA in the calculation process, and the software package was GSVA. The immune score was T-cell infiltration rate of that calculated by quantiseq <sup><xref ref-type="bibr" rid="c99">99</xref></sup>. The gene sets that calculated the mitosis score were obtained from gene ontology (GO:0140014).</p>
</sec>
</sec>
<sec id="d1e1471" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="d1e1459">
<label>Supplemental Figure</label>
<media xlink:href="supplements/581166_file04.pdf"/>
</supplementary-material>
<supplementary-material id="d1e1466">
<label>Supplemental Table</label>
<media xlink:href="supplements/581166_file05.pdf"/>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was supported by the National Key Research and Development Program of China (grants 2022YFA1103900 to H.J., F.L.; 2020YFA0803300 to H.J.); the National Natural Science Foundation of China (grants 82341002 to H.J., 32293192 to H.J., 82030083 to H.J., 82173340 to L.H., 82273400 to Y.J., 32100593 to X.T., 82203306 to W.H., 82372763 to X.W., 82303916 to C.G., 82303039 to Z.Q., 82141101 to F.L., 2022hwyq16 to F.L., 82372794 to F.L.); the Basic Frontier Scientific Research Program of Chinese Academy of Science (ZDBS-LY-SM006 to H.J.); the Innovative research team of high-level local universities in Shanghai (SSMU-ZLCX20180500 to H.J.); Science and Technology Commission of Shanghai Municipality (21ZR1470300 to L.H.).</p>
</ack>
<sec id="s5">
<title>Author Contributions</title>
<p>H.J. and F.L. conceived the idea and designed the analysis. X.C. performed all bioinformatics analyses. Y.Y., X.L. and L.C. provided technical assistance and helpful comments. H.J., F.L. and X.C. wrote the manuscript. All authors approved the final version.</p>
</sec>
<sec id="s6">
<title>Disclosure of conflicts of interest</title>
<p>The authors declare that there is no conflict of interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tomczak</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Czerwinska</surname>, <given-names>P.</given-names></string-name>, and <string-name><surname>Wiznerowicz</surname>, <given-names>M</given-names></string-name></person-group>. (<year>2015</year>). <article-title>The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge</article-title>. <source>Contemp Oncol (Pozn</source>) <volume>19</volume>, <fpage>A68</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.5114/wo.2014.47136</pub-id>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research, N.</collab>, <string-name><surname>Weinstein</surname>, <given-names>J.N.</given-names></string-name>, <string-name><surname>Collisson</surname>, <given-names>E.A.</given-names></string-name>, <string-name><surname>Mills</surname>, <given-names>G.B.</given-names></string-name>, <string-name><surname>Shaw</surname>, <given-names>K.R.</given-names></string-name>, <string-name><surname>Ozenberger</surname>, <given-names>B.A.</given-names></string-name>, <string-name><surname>Ellrott</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Shmulevich</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Sander</surname>, <given-names>C.</given-names></string-name>, and <string-name><surname>Stuart</surname>, <given-names>J.M.</given-names></string-name></person-group> (<year>2013</year>). <article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>. <source>Nat Genet</source> <volume>45</volume>, <fpage>1113</fpage>–<lpage>1120</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2764</pub-id>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Lichtenberg</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Hoadley</surname>, <given-names>K.A.</given-names></string-name>, <string-name><surname>Poisson</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Lazar</surname>, <given-names>A.J.</given-names></string-name>, <string-name><surname>Cherniack</surname>, <given-names>A.D.</given-names></string-name>, <string-name><surname>Kovatich</surname>, <given-names>A.J.</given-names></string-name>, <string-name><surname>Benz</surname>, <given-names>C.C.</given-names></string-name>, <string-name><surname>Levine</surname>, <given-names>D.A.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>A.V.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics</article-title>. <source>Cell</source> <volume>173</volume>, <fpage>400</fpage>–<lpage>416.e411.</lpage> <pub-id pub-id-type="doi">10.1016/j.cell.2018.02.052</pub-id>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smeltzer</surname>, <given-names>M.P.</given-names></string-name>, <string-name><surname>Faris</surname>, <given-names>N.R.</given-names></string-name>, <string-name><surname>Ray</surname>, <given-names>M.A.</given-names></string-name>, and <string-name><surname>Osarogiagbon</surname>, <given-names>R.U</given-names></string-name></person-group>. (<year>2018</year>). <article-title>Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent</article-title>. <source>JAMA Oncol</source> <volume>4</volume>, <fpage>80</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2017.2993</pub-id>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miyauchi</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Morita</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Nakamura</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hosomi</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Watanabe</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ikeda</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Seike</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Fujita</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Minato</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ko</surname>, <given-names>R.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>). <article-title>Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR. J Clin Oncol</article-title>, <source>JCO</source><volume>2102911</volume>. <pub-id pub-id-type="doi">10.1200/JCO.21.02911</pub-id>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Teh</surname>, <given-names>S.H.</given-names></string-name>, <string-name><surname>Uong</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>T.Y.</given-names></string-name>, <string-name><surname>Shiraga</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Gong</surname>, <given-names>I.Y.</given-names></string-name>, <string-name><surname>Herrinton</surname>, <given-names>L.J.</given-names></string-name>, and <string-name><surname>Li</surname>, <given-names>R.A</given-names></string-name></person-group>. (<year>2021</year>). <article-title>Clinical Outcomes Following Regionalization of Gastric Cancer Care in a US Integrated Health Care System</article-title>. <source>J Clin Oncol</source> <volume>39</volume>, <fpage>3364</fpage>–<lpage>3376</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.21.00480</pub-id>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gimotty</surname>, <given-names>P.A.</given-names></string-name>, <string-name><surname>Van Belle</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Elder</surname>, <given-names>D.E.</given-names></string-name>, <string-name><surname>Murry</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Montone</surname>, <given-names>K.T.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Hotz</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Raines</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ming</surname>, <given-names>M.E.</given-names></string-name>, <string-name><surname>Wahl</surname>, <given-names>P.</given-names></string-name>, and <string-name><surname>Guerry</surname>, <given-names>D.</given-names></string-name></person-group> (<year>2005</year>). <article-title>Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma</article-title>. <source>J Clin Oncol</source> <volume>23</volume>, <fpage>8048</fpage>–<lpage>8056</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2005.02.0735</pub-id>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Lv</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Qian</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Shen</surname>, <given-names>Y</given-names></string-name></person-group>. (<year>2021</year>). <article-title>Correlation analysis of Ki67 and CK7 expression with clinical characteristics and prognosis of postoperative cervical adenocarcinoma patients</article-title>. <source>Ann Palliat Med</source> <volume>10</volume>, <fpage>9544</fpage>–<lpage>9552</lpage>. <pub-id pub-id-type="doi">10.21037/apm-21-1974</pub-id>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mouabbi</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Singareeka Raghavendra</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bassett</surname>, <given-names>R.L.</given-names>, <suffix>Jr.</suffix></string-name>, <string-name><surname>Hassan</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Tripathy</surname>, <given-names>D.</given-names></string-name>, and <string-name><surname>Layman</surname>, <given-names>R.M</given-names></string-name></person-group>. (<year>2023</year>). <article-title>Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy</article-title>. <source>JAMA Netw Open</source> <volume>6</volume>, <fpage>e2313017</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.13017</pub-id>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kang</surname>, <given-names>Y.J.</given-names></string-name>, <string-name><surname>Oh</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Bae</surname>, <given-names>S.Y.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>E.K.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>Y.J.</given-names></string-name>, <string-name><surname>Park</surname>, <given-names>E.H.</given-names></string-name>, <string-name><surname>Jeong</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Park</surname>, <given-names>H.K.</given-names></string-name>, <string-name><surname>Suh</surname>, <given-names>Y.J.</given-names></string-name>, and <string-name><surname>Kim</surname>, <given-names>Y.S</given-names></string-name></person-group>. (<year>2023</year>). <article-title>Predictive biological factors for late survival in patients with HER2-positive breast cancer</article-title>. <source>Sci Rep</source> <volume>13</volume>, <issue>11008</issue>. <pub-id pub-id-type="doi">10.1038/s41598-023-38200-y</pub-id>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cai</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Fu</surname>, <given-names>Q.</given-names></string-name>, and <string-name><surname>Chen</surname>, <given-names>A</given-names></string-name></person-group>. (<year>2022</year>). <article-title>The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis</article-title>. <source>World J Surg Oncol</source> <volume>20</volume>, <issue>40</issue>. <pub-id pub-id-type="doi">10.1186/s12957-022-02511-7</pub-id>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Xiong</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Liang</surname>, <given-names>H.</given-names></string-name>, and <string-name><surname>Luo</surname>, <given-names>X</given-names></string-name></person-group>. (<year>2021</year>). <article-title>The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis</article-title>. <source>J Orthop Surg Res</source> <volume>16</volume>, <issue>738</issue>. <pub-id pub-id-type="doi">10.1186/s13018-021-02888-3</pub-id>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lai</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>OuYang</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Sheng</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Lai</surname>, <given-names>B.</given-names></string-name>, and <string-name><surname>Zhou</surname>, <given-names>M</given-names></string-name></person-group>. (<year>2021</year>). <article-title>Novel prognostic genes and subclasses of acute myeloid leukemia revealed by survival analysis of gene expression data</article-title>. <source>BMC Med Genomics</source> <volume>14</volume>, <issue>39</issue>. <pub-id pub-id-type="doi">10.1186/s12920-021-00888-0</pub-id>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anton</surname>, <given-names>R.C.</given-names></string-name>, <string-name><surname>Coffey</surname>, <given-names>D.M.</given-names></string-name>, <string-name><surname>Gondo</surname>, <given-names>M.M.</given-names></string-name>, <string-name><surname>Stephenson</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Brown</surname>, <given-names>R.W.</given-names></string-name>, and <string-name><surname>Cagle</surname>, <given-names>P.T</given-names></string-name></person-group>. (<year>2000</year>). <article-title>The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung</article-title>. <source>Mod Pathol</source> <volume>13</volume>, <fpage>1167</fpage>–<lpage>1172</lpage>. <pub-id pub-id-type="doi">10.1038/modpathol.3880215</pub-id>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Esposito</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Baldi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>De Luca</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Tonini</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Vincenzi</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Santini</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Persichetti</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Mancini</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Citro</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Baldi</surname>, <given-names>F.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2005</year>). <article-title>Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer</article-title>. <source>J Clin Pathol</source> <volume>58</volume>, <fpage>734</fpage>–<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1136/jcp.2004.023531</pub-id>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dworakowska</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Jassem</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Jassem</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Boltze</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Wiedorn</surname>, <given-names>K.H.</given-names></string-name>, <string-name><surname>Dworakowski</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Skokowski</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Jaskiewicz</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Czestochowska</surname>, <given-names>E</given-names></string-name></person-group>. (<year>2005</year>). <article-title>Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC)</article-title>. <source>J Cancer Res Clin Oncol</source> <volume>131</volume>, <fpage>479</fpage>–<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1007/s00432-004-0661-9</pub-id>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freedman</surname>, <given-names>L.S</given-names></string-name></person-group>. (<year>1982</year>). <article-title>Tables of the number of patients required in clinical trials using the logrank test</article-title>. <source>Stat Med</source> <volume>1</volume>, <fpage>121</fpage>–<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1002/sim.4780010204</pub-id>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yao</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Ireland</surname>, <given-names>S.K.</given-names></string-name>, <string-name><surname>Pham</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Temple</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Raj</surname>, <given-names>M.H.</given-names></string-name>, and <string-name><surname>Biliran</surname>, <given-names>H</given-names></string-name></person-group>. (<year>2014</year>). <article-title>TLE1 promotes EMT in A549 lung cancer cells through suppression of E-cadherin</article-title>. <source>Biochem Biophys Res Commun</source> <volume>455</volume>, <fpage>277</fpage>–<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2014.11.007</pub-id>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Tian</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Ren</surname>, <given-names>P.</given-names></string-name>, and <string-name><surname>Yang</surname>, <given-names>Q</given-names></string-name></person-group>. (<year>2021</year>). <article-title>G protein gamma 7 suppresses progression of lung adenocarcinoma by inhibiting E2F transcription factor 1</article-title>. <source>Int J Biol Macromol</source> <volume>182</volume>, <fpage>858</fpage>–<lpage>865</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.04.082</pub-id>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Q.</given-names></string-name>, and <string-name><surname>Wang</surname>, <given-names>K</given-names></string-name></person-group>. (<year>2022</year>). <article-title>MicroRNA-218-5p affects lung adenocarcinoma progression through targeting endoplasmic reticulum oxidoreductase 1 alpha</article-title>. <source>Bioengineered</source> <volume>13</volume>, <fpage>10061</fpage>–<lpage>10070</lpage>. <pub-id pub-id-type="doi">10.1080/21655979.2022.2063537</pub-id>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Yuan</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Pan</surname>, <given-names>Y.</given-names></string-name>, and <string-name><surname>Qi</surname>, <given-names>D</given-names></string-name></person-group>. (<year>2019</year>). <article-title>Overexpression of ANLN in lung adenocarcinoma is associated with metastasis</article-title>. <source>Thorac Cancer</source> <volume>10</volume>, <fpage>1702</fpage>–<lpage>1709</lpage>. <pub-id pub-id-type="doi">10.1111/1759-7714.13135</pub-id>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lv</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Si</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Xiong</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Ding</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Ma</surname>, <given-names>Y.</given-names></string-name>, and <string-name><surname>Yang</surname>, <given-names>Y</given-names></string-name></person-group>. (<year>2018</year>). <article-title>BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1</article-title>. <source>Theranostics</source> <volume>8</volume>, <fpage>5890</fpage>–<lpage>5902</lpage>. <pub-id pub-id-type="doi">10.7150/thno.27667</pub-id>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Zhai</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Lv</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Xu</surname>, <given-names>J</given-names></string-name></person-group>. (<year>2020</year>). <article-title>LINC02418 promotes malignant behaviors in lung adenocarcinoma cells by sponging miR-4677-3p to upregulate KNL1 expression</article-title>. <source>BMC Pulm Med</source> <volume>20</volume>, <issue>217</issue>. <pub-id pub-id-type="doi">10.1186/s12890-020-01229-0</pub-id>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huo</surname>, <given-names>S.F.</given-names></string-name>, <string-name><surname>Shang</surname>, <given-names>W.L.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ren</surname>, <given-names>X.P.</given-names></string-name>, <string-name><surname>Wen</surname>, <given-names>H.X.</given-names></string-name>, <string-name><surname>Chai</surname>, <given-names>C.Y.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Hui</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>L.H.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>S.H.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2020</year>). <article-title>STEAP1 facilitates metastasis and epithelial-mesenchymal transition of lung adenocarcinoma via the JAK2/STAT3 signaling pathway</article-title>. <source>Biosci Rep</source> <volume>40</volume>. <pub-id pub-id-type="doi">10.1042/BSR20193169</pub-id>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Tan</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Gao</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>He</surname>, <given-names>J</given-names></string-name></person-group>. (<year>2018</year>). <article-title>mTOR up-regulation of BEX4 promotes lung adenocarcinoma cell proliferation by potentiating OCT4</article-title>. <source>Biochem Biophys Res Commun</source> <volume>500</volume>, <fpage>302</fpage>–<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2018.04.064</pub-id>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fan</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Tian</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Xue</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>C.</given-names></string-name>, and <string-name><surname>He</surname>, <given-names>J</given-names></string-name></person-group>. (<year>2022</year>). <article-title>Transmembrane Protein-Based Risk Model and H3K4me3 Modification Characteristics in Lung Adenocarcinoma</article-title>. <source>Frontiers in Oncology</source> <volume>12</volume>. <pub-id pub-id-type="doi">10.3389/fonc.2022.828814</pub-id>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kang</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Shin</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Jeon</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Youn</surname>, <given-names>H.</given-names></string-name>, and <string-name><surname>Youn</surname>, <given-names>B</given-names></string-name></person-group>. (<year>2021</year>). <article-title>BEX1 and BEX4 Induce GBM Progression through Regulation of Actin Polymerization and Activation of YAP/TAZ Signaling</article-title>. <source>Int J Mol Sci</source> <volume>22</volume>. <pub-id pub-id-type="doi">10.3390/ijms22189845</pub-id>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gao</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>J.Z.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>S.Q.</given-names></string-name>, <string-name><surname>Chu</surname>, <given-names>C.Y.</given-names></string-name>, <string-name><surname>Chan</surname>, <given-names>J.Y.</given-names></string-name>, and <string-name><surname>Wong</surname>, <given-names>T.S</given-names></string-name></person-group>. (<year>2016</year>). <article-title>Decreased brain-expressed X-linked 4 (BEX4) expression promotes growth of oral squamous cell carcinoma</article-title>. <source>J Exp Clin Cancer Res</source> <volume>35</volume>, <issue>92</issue>. <pub-id pub-id-type="doi">10.1186/s13046-016-0355-6</pub-id>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Luo</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ejaz</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Liang</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2019</year>). <article-title>PGK1-mediated cancer progression and drug resistance</article-title>. <source>Am J Cancer Res</source> <volume>9</volume>, <fpage>2280</fpage>–<lpage>2302</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matsuura</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Sawai</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ikeo</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ogawa</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Iio</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Isogawa</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Shimada</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Komori</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Toyoda</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Kumada</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2017</year>). <article-title>Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection</article-title>. <source>Gastroenterology</source> <volume>152</volume>, <fpage>1383</fpage>–<lpage>1394</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2017.01.041</pub-id>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Poplawski</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Alseekh</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Jankowska</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Skupien-Rabian</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Iwanicka-Nowicka</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Kossowska</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Fogtman</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Rybicka</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Boguslawska</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Adamiok-Ostrowska</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2023</year>). <article-title>Coordinated reprogramming of renal cancer transcriptome, metabolome and secretome associates with immune tumor infiltration</article-title>. <source>Cancer Cell Int</source> <volume>23</volume>, <issue>2</issue>. <pub-id pub-id-type="doi">10.1186/s12935-022-02845-y</pub-id>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Fang</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Songyang</surname>, <given-names>Z.</given-names></string-name>, and <string-name><surname>Xiong</surname>, <given-names>Y</given-names></string-name></person-group>. (<year>2023</year>). <article-title>Pan-cancer investigation of C-to-U editing reveals its important role in cancer development and new targets for cancer treatment</article-title>. <source>Front Oncol</source> <volume>13</volume>, <issue>1097667</issue>. <pub-id pub-id-type="doi">10.3389/fonc.2023.1097667</pub-id>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Povero</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Johnson</surname>, <given-names>S.M.</given-names></string-name>, and <string-name><surname>Liu</surname>, <given-names>J</given-names></string-name></person-group>. (<year>2020</year>). <article-title>Hypoxia, hypoxia-inducible gene 2 (HIG2)/HILPDA, and intracellular lipolysis in cancer</article-title>. <source>Cancer Lett</source> <volume>493</volume>, <fpage>71</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2020.06.013</pub-id>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erfani</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Hua</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Pan</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>B.P.</given-names></string-name>, and <string-name><surname>Yang</surname>, <given-names>X.H</given-names></string-name></person-group>. (<year>2021</year>). <article-title>The Context-Dependent Impact of Integrin-Associated CD151 and Other Tetraspanins on Cancer Development and Progression: A Class of Versatile Mediators of Cellular Function and Signaling</article-title>, <source>Tumorigenesis and Metastasis. Cancers (Basel</source>) <volume>13</volume>. <pub-id pub-id-type="doi">10.3390/cancers13092005</pub-id>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Won</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Park</surname>, <given-names>K.A.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ju</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Ko</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Yoo</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ro</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Oh</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>E.G.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>). <article-title>ANKRD13a controls early cell-death checkpoint by interacting with RIP1 independent of NF-kappaB</article-title>. <source>Cell Death Differ</source> <volume>29</volume>, <fpage>1152</fpage>–<lpage>1163</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-021-00906-9</pub-id>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Tian</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Liang</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Gong</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Mathy</surname>, <given-names>N.W.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Chen</surname>, <given-names>X</given-names></string-name></person-group>. (<year>2020</year>). <article-title>m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation</article-title>. <source>Oncol Rep</source> <volume>44</volume>, <fpage>973</fpage>–<lpage>986</lpage>. <pub-id pub-id-type="doi">10.3892/or.2020.7665</pub-id>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Jia</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Duan</surname>, <given-names>L.</given-names></string-name>, and <string-name><surname>Lu</surname>, <given-names>C</given-names></string-name></person-group>. (<year>2016</year>). <article-title>MicroRNA-1915-3p prevents the apoptosis of lung cancer cells by downregulating DRG2 and PBX2</article-title>. <source>Mol Med Rep</source> <volume>13</volume>, <fpage>505</fpage>–<lpage>512</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2015.4565</pub-id>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mead</surname>, <given-names>T.J</given-names></string-name></person-group>. (<year>2022</year>). <article-title>ADAMTS6: Emerging roles in cardiovascular, musculoskeletal and cancer biology</article-title>. <source>Front Mol Biosci</source> <volume>9</volume>, <issue>1023511</issue>. <pub-id pub-id-type="doi">10.3389/fmolb.2022.1023511</pub-id>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>, <given-names>B.Y.</given-names></string-name>, <string-name><surname>Song</surname>, <given-names>J.W.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>H.Z.</given-names></string-name>, <string-name><surname>Xing</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>Z.H.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>C.Y.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>T.Y.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>Z.N.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Y.N.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.F.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>PSMB8 regulates glioma cell migration, proliferation, and apoptosis through modulating ERK1/2 and PI3K/AKT signaling pathways</article-title>. <source>Biomed Pharmacother</source> <volume>100</volume>, <fpage>205</fpage>–<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.01.170</pub-id>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keshet</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Adler</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Iraqi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ariav</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Lim</surname>, <given-names>L.Q.J.</given-names></string-name>, <string-name><surname>Lerner</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Rabinovich</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Oren</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Katzir</surname>, <given-names>R.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2020</year>). <article-title>Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors</article-title>. <source>Nat Cancer</source> <volume>1</volume>, <fpage>894</fpage>–<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1038/s43018-020-0106-7</pub-id>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Palaparti</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Baratz</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Stifani</surname>, <given-names>S</given-names></string-name></person-group>. (<year>1997</year>). <article-title>The Groucho/Transducin-like Enhancer of split Transcriptional Repressors Interact with the Genetically Defined Amino-terminal Silencing Domain of Histone H3</article-title>. <source>Journal of Biological Chemistry</source> <volume>272</volume>, <fpage>26604</fpage>–<lpage>26610</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.272.42.26604</pub-id>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Ge</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Xiao</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Peng</surname>, <given-names>Q.</given-names></string-name>, and <string-name><surname>Zheng</surname>, <given-names>Z</given-names></string-name></person-group>. (<year>2023</year>). <article-title>The activity of cuproptosis pathway calculated by AUCell algorithm was employed to construct cuproptosis landscape in lung adenocarcinoma</article-title>. <source>Discover Oncology</source> <volume>14</volume>. <pub-id pub-id-type="doi">10.1007/s12672-023-00755-7</pub-id>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Jiang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Meisenhelder</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Hawke</surname>, <given-names>D.H.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Xia</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Aldape</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>He</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Hunter</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis</article-title>. <source>Mol Cell</source> <volume>61</volume>, <fpage>705</fpage>–<lpage>719</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2016.02.009</pub-id>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname>, <given-names>Q.</given-names></string-name>, and <string-name><surname>Yu</surname>, <given-names>Z</given-names></string-name></person-group>. (<year>2020</year>). <article-title>Phosphoglycerate kinase 1 (PGK1) in cancer: A promising target for diagnosis and therapy</article-title>. <source>Life Sci</source> <volume>256</volume>, <issue>117863</issue>. <pub-id pub-id-type="doi">10.1016/j.lfs.2020.117863</pub-id>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Waldman</surname>, <given-names>A.D.</given-names></string-name>, <string-name><surname>Fritz</surname>, <given-names>J.M.</given-names></string-name>, and <string-name><surname>Lenardo</surname>, <given-names>M.J</given-names></string-name></person-group>. (<year>2020</year>). <article-title>A guide to cancer immunotherapy: from T cell basic science to clinical practice</article-title>. <source>Nat Rev Immunol</source> <volume>20</volume>, <fpage>651</fpage>–<lpage>668</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-0306-5</pub-id>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Hao</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Z.</given-names></string-name>, and <string-name><surname>Chu</surname>, <given-names>X</given-names></string-name></person-group>. (<year>2019</year>). <article-title>Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis</article-title>. <source>Cell Transplant</source> <volume>28</volume>, <fpage>76S</fpage>–<lpage>86S</lpage> <pub-id pub-id-type="doi">10.1177/0963689719893950</pub-id>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hwang</surname>, <given-names>L.H.</given-names></string-name>, <string-name><surname>Lau</surname>, <given-names>L.F.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>D.L.</given-names></string-name>, <string-name><surname>Mistrot</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Hardwick</surname>, <given-names>K.G.</given-names></string-name>, <string-name><surname>Hwang</surname>, <given-names>E.S.</given-names></string-name>, <string-name><surname>Amon</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Murray</surname>, <given-names>A.W</given-names></string-name></person-group>. (<year>1998</year>). <article-title>Budding yeast Cdc20: a target of the spindle checkpoint</article-title>. <source>Science</source> <volume>279</volume>, <fpage>1041</fpage>–<lpage>1044</lpage>. <pub-id pub-id-type="doi">10.1126/science.279.5353.1041</pub-id>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uuskula-Reimand</surname>, <given-names>L.</given-names></string-name>, and <string-name><surname>Wilson</surname>, <given-names>M.D</given-names></string-name></person-group>. (<year>2022</year>). <article-title>Untangling the roles of TOP2A and TOP2B in transcription and cancer</article-title>. <source>Sci Adv</source> <volume>8</volume>, <fpage>eadd4920</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.add4920</pub-id>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lamers</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>van der Ploeg</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Schild</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Ebus</surname>, <given-names>M.E.</given-names></string-name>, <string-name><surname>Koster</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Hansen</surname>, <given-names>B.R.</given-names></string-name>, <string-name><surname>Koch</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Versteeg</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Caron</surname>, <given-names>H.N.</given-names></string-name>, and <string-name><surname>Molenaar</surname>, <given-names>J.J.</given-names></string-name></person-group> (<year>2011</year>). <article-title>Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe</article-title>. <source>Endocr Relat Cancer</source> <volume>18</volume>, <fpage>657</fpage>–<lpage>668</lpage>. <pub-id pub-id-type="doi">10.1530/ERC-11-0207</pub-id>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wittmann</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Wilm</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Karsenti</surname>, <given-names>E.</given-names></string-name>, and <string-name><surname>Vernos</surname>, <given-names>I</given-names></string-name></person-group>. (<year>2000</year>). <article-title>TPX2, A novel xenopus MAP involved in spindle pole organization</article-title>. <source>J Cell Biol</source> <volume>149</volume>, <fpage>1405</fpage>–<lpage>1418</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.149.7.1405</pub-id>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kufer</surname>, <given-names>T.A.</given-names></string-name>, <string-name><surname>Sillje</surname>, <given-names>H.H.</given-names></string-name>, <string-name><surname>Korner</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Gruss</surname>, <given-names>O.J.</given-names></string-name>, <string-name><surname>Meraldi</surname>, <given-names>P.</given-names></string-name>, and <string-name><surname>Nigg</surname>, <given-names>E.A</given-names></string-name></person-group>. (<year>2002</year>). <article-title>Human TPX2 is required for targeting Aurora-A kinase to the spindle</article-title>. <source>J Cell Biol</source> <volume>158</volume>, <fpage>617</fpage>–<lpage>623</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200204155</pub-id>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research, N.</collab></person-group> (<year>2014</year>). <article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title>. <source>Nature</source> <volume>511</volume>, <fpage>543</fpage>–<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1038/nature13385</pub-id>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Kelly</surname>, <given-names>M.R.</given-names></string-name>, <string-name><surname>Ramms</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>Heintschel</surname>, <given-names>M.L.</given-names></string-name>, <string-name><surname>Tao</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Tutuncuoglu</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.J.</given-names></string-name>, <string-name><surname>Ono</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Foussard</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2021</year>). <article-title>Interpretation of cancer mutations using a multiscale map of protein systems</article-title>. <source>Science</source> <volume>374</volume>, <fpage>eabf3067</fpage>. <pub-id pub-id-type="doi">10.1126/science.abf3067</pub-id>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Shi</surname>, <given-names>Y.L.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>L.L.</given-names></string-name>, <string-name><surname>Yan</surname>, <given-names>Z.X.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>Y.L.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>L.L.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>S.W.</given-names></string-name>, <string-name><surname>Chu</surname>, <given-names>H.L.</given-names></string-name>, <string-name><surname>Shi</surname>, <given-names>T.T.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer</article-title>. <source>Cell Death Dis</source> <volume>9</volume>, <issue>739</issue>. <pub-id pub-id-type="doi">10.1038/s41419-018-0776-6</pub-id>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shibata</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Kokubu</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Tsuta</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Hirohashi</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2009</year>). <article-title>Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer</article-title>. <source>Cancer Lett</source> <volume>283</volume>, <fpage>203</fpage>–<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2009.03.038</pub-id>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanker</surname>, <given-names>A.B.</given-names></string-name>, <string-name><surname>Pfefferle</surname>, <given-names>A.D.</given-names></string-name>, <string-name><surname>Balko</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Kuba</surname>, <given-names>M.G.</given-names></string-name>, <string-name><surname>Young</surname>, <given-names>C.D.</given-names></string-name>, <string-name><surname>Sanchez</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Sutton</surname>, <given-names>C.R.</given-names></string-name>, <string-name><surname>Cheng</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Perou</surname>, <given-names>C.M.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>J.J.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2013</year>). <article-title>Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>110</volume>, <fpage>14372</fpage>–<lpage>14377</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1303204110</pub-id>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eng</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Woo</surname>, <given-names>K.M.</given-names></string-name>, <string-name><surname>Sima</surname>, <given-names>C.S.</given-names></string-name>, <string-name><surname>Plodkowski</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hellmann</surname>, <given-names>M.D.</given-names></string-name>, <string-name><surname>Chaft</surname>, <given-names>J.E.</given-names></string-name>, <string-name><surname>Kris</surname>, <given-names>M.G.</given-names></string-name>, <string-name><surname>Arcila</surname>, <given-names>M.E.</given-names></string-name>, <string-name><surname>Ladanyi</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Drilon</surname>, <given-names>A</given-names></string-name></person-group>. (<year>2015</year>). <article-title>Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas</article-title>. <source>J Thorac Oncol</source> <volume>10</volume>, <fpage>1713</fpage>–<lpage>1719</lpage>. <pub-id pub-id-type="doi">10.1097/JTO.0000000000000671</pub-id>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thorsson</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Gibbs</surname>, <given-names>D.L.</given-names></string-name>, <string-name><surname>Brown</surname>, <given-names>S.D.</given-names></string-name>, <string-name><surname>Wolf</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Bortone</surname>, <given-names>D.S.</given-names></string-name>, <string-name><surname>Ou Yang</surname>, <given-names>T.H.</given-names></string-name>, <string-name><surname>Porta-Pardo</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Gao</surname>, <given-names>G.F.</given-names></string-name>, <string-name><surname>Plaisier</surname>, <given-names>C.L.</given-names></string-name>, <string-name><surname>Eddy</surname>, <given-names>J.A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>The Immune Landscape of Cancer</article-title>. <source>Immunity</source> <volume>48</volume>, <fpage>812</fpage>–<lpage>830.e814.</lpage> <pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.023</pub-id>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meigs</surname>, <given-names>T.E.</given-names></string-name>, <string-name><surname>Fedor-Chaiken</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kaplan</surname>, <given-names>D.D.</given-names></string-name>, <string-name><surname>Brackenbury</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Casey</surname>, <given-names>P.J</given-names></string-name></person-group>. (<year>2002</year>). <article-title>Galpha12 and Galpha13 negatively regulate the adhesive functions of cadherin</article-title>. <source>J Biol Chem</source> <volume>277</volume>, <fpage>24594</fpage>–<lpage>24600</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M201984200</pub-id>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>An</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Adams</surname>, <given-names>J.R.</given-names></string-name>, <string-name><surname>Hollern</surname>, <given-names>D.P.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Chang</surname>, <given-names>S.G.</given-names></string-name>, <string-name><surname>Gams</surname>, <given-names>M.S.</given-names></string-name>, <string-name><surname>Chung</surname>, <given-names>P.E.D.</given-names></string-name>, <string-name><surname>He</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Jangra</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Shah</surname>, <given-names>J.S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast</article-title>. <source>Cell Rep</source> <volume>25</volume>, <fpage>702</fpage>–<lpage>714.e706.</lpage> <pub-id pub-id-type="doi">10.1016/j.celrep.2018.09.056</pub-id>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zeisberg</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Neilson</surname>, <given-names>E.G</given-names></string-name></person-group>. (<year>2009</year>). <article-title>Biomarkers for epithelial-mesenchymal transitions</article-title>. <source>J Clin Invest</source> <volume>119</volume>, <fpage>1429</fpage>–<lpage>1437</lpage>. <pub-id pub-id-type="doi">10.1172/JCI36183</pub-id>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Mani</surname>, <given-names>S.A.</given-names></string-name>, <string-name><surname>Donaher</surname>, <given-names>J.L.</given-names></string-name>, <string-name><surname>Ramaswamy</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Itzykson</surname>, <given-names>R.A.</given-names></string-name>, <string-name><surname>Come</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Savagner</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Gitelman</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Richardson</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Weinberg</surname>, <given-names>R.A</given-names></string-name></person-group>. (<year>2004</year>). <article-title>Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis</article-title>. <source>Cell</source> <volume>117</volume>, <fpage>927</fpage>–<lpage>939</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2004.06.006</pub-id>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Egner</surname>, <given-names>J.R</given-names></string-name></person-group>. (<year>2010</year>). <article-title>AJCC cancer staging manual</article-title>. <source>Jama</source> <volume>304</volume>, <fpage>1726</fpage>–<lpage>1727</lpage>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rebello</surname>, <given-names>R.J.</given-names></string-name>, <string-name><surname>Oing</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Knudsen</surname>, <given-names>K.E.</given-names></string-name>, <string-name><surname>Loeb</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Johnson</surname>, <given-names>D.C.</given-names></string-name>, <string-name><surname>Reiter</surname>, <given-names>R.E.</given-names></string-name>, <string-name><surname>Gillessen</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Van der Kwast</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Bristow</surname>, <given-names>R.G.</given-names></string-name></person-group> (<year>2021</year>). <article-title>Prostate cancer</article-title>. <source>Nat Rev Dis Primers</source> <volume>7</volume>, <issue>9</issue>. <pub-id pub-id-type="doi">10.1038/s41572-020-00243-0</pub-id>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname>, <given-names>J.K.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Go</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>H.S.</given-names></string-name>, <string-name><surname>Cho</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Choi</surname>, <given-names>K.S.</given-names></string-name>, <string-name><surname>Ha</surname>, <given-names>G.H.</given-names></string-name>, and <string-name><surname>Lee</surname>, <given-names>C.W</given-names></string-name></person-group>. (<year>2016</year>). <article-title>Oncogenic microtubule hyperacetylation through BEX4-mediated sirtuin 2 inhibition</article-title>. <source>Cell Death Dis</source> <volume>7</volume>, <fpage>e2336</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2016.240</pub-id>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname>, <given-names>J.K.</given-names></string-name>, <string-name><surname>Ha</surname>, <given-names>G.H.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>H.S.</given-names></string-name>, and <string-name><surname>Lee</surname>, <given-names>C.W</given-names></string-name></person-group>. (<year>2018</year>). <article-title>Oncogenic potential of BEX4 is conferred by Polo-like kinase 1-mediated phosphorylation</article-title>. <source>Exp Mol Med</source> <volume>50</volume>, <fpage>1</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/s12276-018-0168-0</pub-id>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beroukhim</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Mermel</surname>, <given-names>C.H.</given-names></string-name>, <string-name><surname>Porter</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Raychaudhuri</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Donovan</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Barretina</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Boehm</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Dobson</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Urashima</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2010</year>). <article-title>The landscape of somatic copy-number alteration across human cancers</article-title>. <source>Nature</source> <volume>463</volume>, <fpage>899</fpage>–<lpage>905</lpage>. <pub-id pub-id-type="doi">10.1038/nature08822</pub-id>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davoli</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>A.W.</given-names></string-name>, <string-name><surname>Mengwasser</surname>, <given-names>K.E.</given-names></string-name>, <string-name><surname>Sack</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Yoon</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Park</surname>, <given-names>P.J.</given-names></string-name>, and <string-name><surname>Elledge</surname>, <given-names>S.J</given-names></string-name></person-group>. (<year>2013</year>). <article-title>Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome</article-title>. <source>Cell</source> <volume>155</volume>, <fpage>948</fpage>–<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.10.011</pub-id>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Girish</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Lakhani</surname>, <given-names>A.A.</given-names></string-name>, <string-name><surname>Thompson</surname>, <given-names>S.L.</given-names></string-name>, <string-name><surname>Scaduto</surname>, <given-names>C.M.</given-names></string-name>, <string-name><surname>Brown</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Hagenson</surname>, <given-names>R.A.</given-names></string-name>, <string-name><surname>Sausville</surname>, <given-names>E.L.</given-names></string-name>, <string-name><surname>Mendelson</surname>, <given-names>B.E.</given-names></string-name>, <string-name><surname>Kandikuppa</surname>, <given-names>P.K.</given-names></string-name>, <string-name><surname>Lukow</surname>, <given-names>D.A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2023</year>). <article-title>Oncogene-like addiction to aneuploidy in human cancers</article-title>. <source>Science</source> <volume>381</volume>, <fpage>eadg4521</fpage>. <pub-id pub-id-type="doi">10.1126/science.adg4521</pub-id>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bosco</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Goldberg</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Mays</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Cheng</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Johnson</surname>, <given-names>A.F.</given-names></string-name>, <string-name><surname>Bianchi</surname>, <given-names>J.J.</given-names></string-name>, <string-name><surname>Toscani</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Di Tommaso</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Katsnelson</surname>, <given-names>L.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2023</year>). <article-title>KaryoCreate: A CRISPR-based technology to study chromosome-specific aneuploidy by targeting human centromeres</article-title>. <source>Cell</source> <volume>186</volume>, <fpage>1985</fpage>–<lpage>2001.e1919.</lpage> <pub-id pub-id-type="doi">10.1016/j.cell.2023.03.029</pub-id>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ha</surname>, <given-names>S.Y.</given-names></string-name>, <string-name><surname>Choi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Park</surname>, <given-names>C.K</given-names></string-name></person-group>. (<year>2016</year>). <article-title>The Prognostic Role of Mitotic Index in Hepatocellular Carcinoma Patients after Curative Hepatectomy</article-title>. <source>Cancer Res Treat</source> <volume>48</volume>, <fpage>180</fpage>–<lpage>189</lpage>. <pub-id pub-id-type="doi">10.4143/crt.2014.321</pub-id>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Liang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Fan</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Jiang</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, and <string-name><surname>Wang</surname>, <given-names>L</given-names></string-name></person-group>. (<year>2018</year>). <article-title>Molecular profiles for insular low-grade gliomas with putamen involvement</article-title>. <source>J Neurooncol</source> <volume>138</volume>, <fpage>659</fpage>–<lpage>666</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-018-2837-1</pub-id>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Makinen</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Laitakari</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Johnson</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Makitaro</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Bloigu</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Paakko</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Lappi-Blanco</surname>, <given-names>E.</given-names></string-name>, and <string-name><surname>Kaarteenaho</surname>, <given-names>R</given-names></string-name></person-group>. (<year>2017</year>). <article-title>Histological features of malignancy correlate with growth patterns and patient outcome in lung adenocarcinoma</article-title>. <source>Histopathology</source> <volume>71</volume>, <fpage>425</fpage>–<lpage>436</lpage>. <pub-id pub-id-type="doi">10.1111/his.13236</pub-id>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Byrne</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Savas</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Sant</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Virassamy</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Luen</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Beavis</surname>, <given-names>P.A.</given-names></string-name>, <string-name><surname>Mackay</surname>, <given-names>L.K.</given-names></string-name>, <string-name><surname>Neeson</surname>, <given-names>P.J.</given-names></string-name>, and <string-name><surname>Loi</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2020</year>). <article-title>Tissue-resident memory T cells in breast cancer control and immunotherapy responses</article-title>. <source>Nat Rev Clin Oncol</source> <volume>17</volume>, <fpage>341</fpage>–<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1038/s41571-020-0333-y</pub-id>.</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Song</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Wang</surname>, <given-names>H</given-names></string-name></person-group>. (<year>2021</year>). <article-title>The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer</article-title>. <source>Biosci Rep</source> <volume>41</volume>. <pub-id pub-id-type="doi">10.1042/BSR20202321</pub-id>.</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ducreux</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Cuhna</surname>, <given-names>A.S.</given-names></string-name>, <string-name><surname>Caramella</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Hollebecque</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Burtin</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Goere</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Seufferlein</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Haustermans</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Van Laethem</surname>, <given-names>J.L.</given-names></string-name>, <string-name><surname>Conroy</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2015</year>). <article-title>Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source> <volume>26</volume> <issue><italic>Suppl 5</italic></issue>, <fpage>v56</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdv295</pub-id>.</mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cardoso</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Kyriakides</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ohno</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Penault-Llorca</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Poortmans</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Rubio</surname>, <given-names>I.T.</given-names></string-name>, <string-name><surname>Zackrisson</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Senkus</surname>, <given-names>E.</given-names></string-name>, and <collab>clinicalguidelines@esmo.org, E.G.C.E.a</collab></person-group>. (<year>2019</year>). <article-title>Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger</article-title>. <source>Ann Oncol</source> <volume>30</volume>, <fpage>1194</fpage>–<lpage>1220</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdz173</pub-id>.</mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oaknin</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bosse</surname>, <given-names>T.J.</given-names></string-name>, <string-name><surname>Creutzberg</surname>, <given-names>C.L.</given-names></string-name>, <string-name><surname>Giornelli</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Harter</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Joly</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Lorusso</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Marth</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Makker</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Mirza</surname>, <given-names>M.R.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>). <article-title>Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source> <volume>33</volume>, <fpage>860</fpage>–<lpage>877</lpage>. <pub-id pub-id-type="doi">10.1016/j.annonc.2022.05.009</pub-id>.</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vogel</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Cervantes</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Chau</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Daniele</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Llovet</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Meyer</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Nault</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Neumann</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Ricke</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Sangro</surname>, <given-names>B.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source> <volume>29</volume>, <fpage>iv238</fpage>–<lpage>iv255</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdy308</pub-id>.</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stupp</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Brada</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>van den Bent</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Tonn</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Pentheroudakis</surname>, <given-names>G.</given-names></string-name>, and <string-name><surname>Group</surname>, <given-names>E.G.W.</given-names></string-name></person-group> (<year>2014</year>). <article-title>High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source> <volume>25</volume>, <fpage>iii93</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdu050</pub-id>.</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Postmus</surname>, <given-names>P.E.</given-names></string-name>, <string-name><surname>Kerr</surname>, <given-names>K.M.</given-names></string-name>, <string-name><surname>Oudkerk</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Senan</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Waller</surname>, <given-names>D.A.</given-names></string-name>, <string-name><surname>Vansteenkiste</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Escriu</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Peters</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Committee</surname>, <given-names>E.G</given-names></string-name></person-group>. (<year>2017</year>). <article-title>Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source> <volume>28</volume>, <fpage>iv1</fpage>–<lpage>iv21</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdx222</pub-id>.</mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gui</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Kosteniuk</surname>, <given-names>S.E.</given-names></string-name>, <string-name><surname>Lau</surname>, <given-names>J.C.</given-names></string-name>, and <string-name><surname>Megyesi</surname>, <given-names>J.F</given-names></string-name></person-group>. (<year>2018</year>). <article-title>Tumor growth dynamics in serially-imaged low-grade glioma patients</article-title>. <source>J Neurooncol</source> <volume>139</volume>, <fpage>167</fpage>–<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-018-2857-x</pub-id>.</mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alvarez</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Benhammou</surname>, <given-names>J.N.</given-names></string-name>, <string-name><surname>Darci-Maher</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>French</surname>, <given-names>S.W.</given-names></string-name>, <string-name><surname>Han</surname>, <given-names>S.B.</given-names></string-name>, <string-name><surname>Sinsheimer</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Agopian</surname>, <given-names>V.G.</given-names></string-name>, <string-name><surname>Pisegna</surname>, <given-names>J.R.</given-names></string-name>, and <string-name><surname>Pajukanta</surname>, <given-names>P</given-names></string-name></person-group>. (<year>2022</year>). <article-title>Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival</article-title>. <source>Genome Med</source> <volume>14</volume>, <issue>50</issue>. <pub-id pub-id-type="doi">10.1186/s13073-022-01055-5</pub-id>.</mixed-citation></ref>
<ref id="c84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Infante</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Berghmans</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Heuvelmans</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Hillerdal</surname>, <given-names>G.</given-names></string-name>, and <string-name><surname>Oudkerk</surname>, <given-names>M</given-names></string-name></person-group>. (<year>2013</year>). <article-title>Slow-growing lung cancer as an emerging entity: from screening to clinical management</article-title>. <source>Eur Respir J</source> <volume>42</volume>, <fpage>1706</fpage>–<lpage>1722</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00186212</pub-id>.</mixed-citation></ref>
<ref id="c85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoshino</surname>, <given-names>T</given-names></string-name></person-group>. (<year>1984</year>). <article-title>A commentary on the biology and growth kinetics of low-grade and high-grade gliomas</article-title>. <source>J Neurosurg</source> <volume>61</volume>, <fpage>895</fpage>–<lpage>900</lpage>. <pub-id pub-id-type="doi">10.3171/jns.1984.61.5.0895</pub-id>.</mixed-citation></ref>
<ref id="c86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sajjadi</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Venetis</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Piciotti</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Invernizzi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Guerini-Rocco</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Haricharan</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Fusco</surname>, <given-names>N</given-names></string-name></person-group>. (<year>2021</year>). <article-title>Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization</article-title>. <source>Cancer Cell Int</source> <volume>21</volume>, <issue>266</issue>. <pub-id pub-id-type="doi">10.1186/s12935-021-01976-y</pub-id>.</mixed-citation></ref>
<ref id="c87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Doghri</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Houcine</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Boujelbene</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Driss</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Charfi</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Abbes</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Mrad</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Sellami</surname>, <given-names>R</given-names></string-name></person-group>. (<year>2019</year>). <article-title>Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications</article-title>. <source>Appl Immunohistochem Mol Morphol</source> <volume>27</volume>, <fpage>678</fpage>–<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1097/PAI.0000000000000641</pub-id>.</mixed-citation></ref>
<ref id="c88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>T.Y.</given-names></string-name>, <string-name><surname>Kang</surname>, <given-names>P.M.</given-names></string-name>, <string-name><surname>Qian</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Deng</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>J.H.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>R.W.</given-names></string-name>, <string-name><surname>Jiang</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>F.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance</article-title>. <source>Cancer Chemoth Pharm</source> <volume>77</volume>, <fpage>583</fpage>–<lpage>593</lpage>. <pub-id pub-id-type="doi">10.1007/s00280-016-2969-y</pub-id>.</mixed-citation></ref>
<ref id="c89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Donev</surname>, <given-names>I.S.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Yamada</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Takeuchi</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Matsumoto</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Yamori</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Nishioka</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Sone</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Yano</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2011</year>). <article-title>Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer</article-title>. <source>Clin Cancer Res</source> <volume>17</volume>, <fpage>2260</fpage>–<lpage>2269</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1993</pub-id>.</mixed-citation></ref>
<ref id="c90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Shi</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>H.Z.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Zheng</surname>, <given-names>T</given-names></string-name></person-group>. (<year>2021</year>). <article-title>The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response</article-title>. <source>NPJ Precis Oncol</source> <volume>5</volume>, <issue>56</issue>. <pub-id pub-id-type="doi">10.1038/s41698-021-00200-4</pub-id>.</mixed-citation></ref>
<ref id="c91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brown</surname>, <given-names>T.J.</given-names></string-name>, <string-name><surname>Bota</surname>, <given-names>D.A.</given-names></string-name>, <string-name><surname>van Den Bent</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Brown</surname>, <given-names>P.D.</given-names></string-name>, <string-name><surname>Maher</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Aregawi</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Liau</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Buckner</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Weller</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Berger</surname>, <given-names>M.S.</given-names></string-name>, and <string-name><surname>Glantz</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2019</year>). <article-title>Management of low-grade glioma: a systematic review and meta-analysis</article-title>. <source>Neurooncol Pract</source> <volume>6</volume>, <fpage>249</fpage>–<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1093/nop/npy034</pub-id>.</mixed-citation></ref>
<ref id="c92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Ma</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zou</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Gong</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Gao</surname>, <given-names>X.</given-names></string-name>, and <string-name><surname>Liang</surname>, <given-names>G</given-names></string-name></person-group>. (<year>2022</year>). <article-title>Clinical characteristics and prognosis of patients with glioblastoma: A review of survival analysis of 1674 patients based on SEER database</article-title>. <source>Medicine (Baltimore</source>) <volume>101</volume>, <fpage>e32042</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000032042</pub-id>.</mixed-citation></ref>
<ref id="c93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shannon</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Markiel</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ozier</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Baliga</surname>, <given-names>N.S.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>J.T.</given-names></string-name>, <string-name><surname>Ramage</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Amin</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Schwikowski</surname>, <given-names>B.</given-names></string-name>, and <string-name><surname>Ideker</surname>, <given-names>T</given-names></string-name></person-group>. (<year>2003</year>). <article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>. <source>Genome Res</source> <volume>13</volume>, <fpage>2498</fpage>–<lpage>2504</lpage>. <pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>.</mixed-citation></ref>
<ref id="c94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>L.G.</given-names></string-name>, <string-name><surname>Han</surname>, <given-names>Y.</given-names></string-name>, and <string-name><surname>He</surname>, <given-names>Q.Y</given-names></string-name></person-group>. (<year>2012</year>). <article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title>. <source>OMICS</source> <volume>16</volume>, <fpage>284</fpage>–<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id>.</mixed-citation></ref>
<ref id="c95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mayakonda</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>D.C.</given-names></string-name>, <string-name><surname>Assenov</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Plass</surname>, <given-names>C.</given-names></string-name>, and <string-name><surname>Koeffler</surname>, <given-names>H.P</given-names></string-name></person-group>. (<year>2018</year>). <article-title>Maftools: efficient and comprehensive analysis of somatic variants in cancer</article-title>. <source>Genome Res</source> <volume>28</volume>, <fpage>1747</fpage>–<lpage>1756</lpage>. <pub-id pub-id-type="doi">10.1101/gr.239244.118</pub-id>.</mixed-citation></ref>
<ref id="c96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tsherniak</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Vazquez</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Montgomery</surname>, <given-names>P.G.</given-names></string-name>, <string-name><surname>Weir</surname>, <given-names>B.A.</given-names></string-name>, <string-name><surname>Kryukov</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Cowley</surname>, <given-names>G.S.</given-names></string-name>, <string-name><surname>Gill</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Harrington</surname>, <given-names>W.F.</given-names></string-name>, <string-name><surname>Pantel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Krill-Burger</surname>, <given-names>J.M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2017</year>). <article-title>Defining a Cancer Dependency Map</article-title>. <source>Cell</source> <volume>170</volume>, <fpage>564</fpage>–<lpage>576.e516.</lpage> <pub-id pub-id-type="doi">10.1016/j.cell.2017.06.010</pub-id>.</mixed-citation></ref>
<ref id="c97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Soares</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Greninger</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Edelman</surname>, <given-names>E.J.</given-names></string-name>, <string-name><surname>Lightfoot</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Forbes</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Bindal</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Beare</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Thompson</surname>, <given-names>I.R.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2013</year>). <article-title>Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells</article-title>. <source>Nucleic Acids Res</source> <volume>41</volume>, <fpage>D955</fpage>–<lpage>961</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks1111</pub-id>.</mixed-citation></ref>
<ref id="c98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Narayan</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Corsello</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Peck</surname>, <given-names>D.D.</given-names></string-name>, <string-name><surname>Natoli</surname>, <given-names>T.E.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Gould</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Davis</surname>, <given-names>J.F.</given-names></string-name>, <string-name><surname>Tubelli</surname>, <given-names>A.A.</given-names></string-name>, <string-name><surname>Asiedu</surname>, <given-names>J.K.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2017</year>). <article-title>A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles</article-title>. <source>Cell</source> <volume>171</volume>, <fpage>1437</fpage>–<lpage>1452.e1417.</lpage> <pub-id pub-id-type="doi">10.1016/j.cell.2017.10.049</pub-id>.</mixed-citation></ref>
<ref id="c99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Finotello</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Mayer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Plattner</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Laschober</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Rieder</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Hackl</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Krogsdam</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Loncova</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Posch</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Wilflingseder</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data</article-title>. <source>Genome Med</source> <volume>11</volume>, <issue>34</issue>. <pub-id pub-id-type="doi">10.1186/s13073-019-0638-6</pub-id>.</mixed-citation></ref>
<ref id="c100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sturm</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Finotello</surname>, <given-names>F.</given-names></string-name>, and <string-name><surname>List</surname>, <given-names>M</given-names></string-name></person-group>. (<year>2020</year>). <article-title>Immunedeconv: An R Package for Unified Access to Computational Methods for Estimating Immune Cell Fractions from Bulk RNA-Sequencing Data</article-title>. <source>Methods Mol Biol</source> <volume>2120</volume>, <fpage>223</fpage>–<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-0716-0327-7_16</pub-id>.</mixed-citation></ref>
<ref id="c101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanzelmann</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Castelo</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Guinney</surname>, <given-names>J</given-names></string-name></person-group>. (<year>2013</year>). <article-title>GSVA: gene set variation analysis for microarray and RNA-seq data</article-title>. <source>BMC Bioinformatics</source> <volume>14</volume>, <issue>7</issue>. <pub-id pub-id-type="doi">10.1186/1471-2105-14-7</pub-id>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101619.1.sa4</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Archer</surname>
<given-names>Graeme</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>GlaxoSmithKline</institution>
</institution-wrap>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Incomplete</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>This paper contains <bold>valuable</bold> ideas for methodology concerned with the identification of genes associated with disease prognosis in a broad range of cancers. However, there are concerns that the statistical properties of MEMORY are <bold>incompletely</bold> investigated and described. Further, more precise details about the implementation of the method would increase the replicability of the findings by other researchers.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101619.1.sa3</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The authors propose a new technique which they name &quot;Multi-gradient Permutation Survival Analysis (MEMORY)&quot; that they use to identify &quot;Genes Steadily Associated with Prognosis (GEARs)&quot; using RNA-seq data from the TCGA database. The contribution of this method is one of the key stated aims of the paper. The vast majority of the paper focuses on various downstream analyses that make use of the specific GEARs identified by MEMORY to derive biological insights, with a particular focus on lung adenocarcinoma (LUAD) and breast invasive carcinoma (BRCA) which are stated to be representative of other cancers and are observed to have enriched mitosis and immune signatures, respectively. Through the lens of these cancers, these signatures are the focus of significant investigation in the paper.</p>
<p>Strengths:</p>
<p>The approach for MEMORY is well-defined and clearly presented, albeit briefly. This affords statisticians and bioinformaticians the ability to effectively scrutinize the proposed methodology and may lead to further advancements in this field.</p>
<p>The scientific aspects of the paper (e.g., the results based on the use of MEMORY and the downstream bioinformatics workflows) are conveyed effectively and in a way that is digestible to an individual who is not deeply steeped in the cancer biology field.</p>
<p>Weaknesses:</p>
<p>I was surprised that comparatively little of the paper is devoted to the justification of MEMORY (i.e., the authors' method) for the identification of genes that are important broadly for the understanding of cancer. The authors' approach is explained in the methods section of the paper, but no rationale is given for why certain aspects of the method are defined as they are. Moreover, no comparison or reference is made to any other methods that have been developed for similar purposes and no results are shown to illustrate the robustness of the proposed method (e.g., is it sensitive to subtle changes in how it is implemented).</p>
<p>For example, in the first part of the MEMORY algorithm, gene expression values are dichotomized at the sample median and a log-rank test is performed. This would seemingly result in an unnecessary loss of information for detecting an association between gene expression and survival. Moreover, while dichotomizing at the median is optimal from an information theory perspective (i.e., it creates equally sized groups), there is no reason to believe that median-dichotomization is correct vis-à-vis the relationship between gene expression and survival. If a gene really matters and expression only differentiates survival more towards the tail of the empirical gene expression distribution, median-dichotomization could dramatically lower the power to detect group-wise differences.</p>
<p>Specifically, the authors' rationale for translating the Significant Probability Matrix into a set of GEARs warrants some discussion in the paper. If I understand correctly, for each cancer the authors propose to search for the smallest sample size (i.e., the smallest value of k_{j}) were there is at least one gene with a survival analysis p-value &lt;0.05 for each of the 1000 sampled datasets. I base my understanding on the statement &quot;We defined the sampling size k_{j} reached saturation when the max value of column j was equal to 1 in a significant-probability matrix. The least value of k_{j} was selected&quot;. Then, any gene with a p-value &lt;0.05 in 80% of the 1000 sampled datasets would be called a GEAR for that cancer. The 80% value here seems arbitrary but that is a minor point. I acknowledge that something must be chosen. More importantly, do the authors believe this logic will work effectively in general? Presumably, the gene with the largest effect for a cancer will define the value of K_{j}, and, if the effect is large, this may result in other genes with smaller effects not being selected for that cancer by virtue of the 80% threshold. One could imagine that a gene that has a small-to-moderate effect consistently across many cancers may not show up as a gear broadly if there are genes with more substantive effects for most of the cancers investigated. I am taking the term &quot;Steadily Associated&quot; very literally here as I've constructed a hypothetical where the association is consistent across cancers but not extremely strong. If by &quot;Steadily Associated&quot; the authors really mean &quot;Relatively Large Association&quot;, my argument would fall apart but then the definition of a GEAR would perhaps be suboptimal. In this latter case, the proposed approach seems like an indirect way to ensure there is a reasonable effect size for a gene's expression on survival.</p>
<p>The paper contains numerous post-hoc hypothesis tests, statements regarding detected associations and correlations, and statements regarding statistically significant findings based on analyses that would naturally only be conducted in light of positive results from analyses upstream in the overall workflow. Due to the number of statistical tests performed and the fact that the tests are sometimes performed using data-driven subgroups (e.g., the mitosis subgroups), it is highly likely that some of the findings in the work will not be replicable. Of course, this is exploratory science, and is to be expected that some findings won't replicate (the authors even call for further research into key findings). Nonetheless, I would encourage the authors to focus on the quantification of evidence regarding associations or claims (i.e., presenting effect estimates and uncertainty intervals), but to avoid the use of the term statistical significance owing to there being no clear plan to control type I error rates in any systematic way across the diverse analyses there were performed.</p>
<p>A prespecified analysis plan with hypotheses to be tested (to the extent this was already produced) and a document that defines the complete scope of the scientific endeavor (beyond that which is included in the paper) would strengthen the contribution by providing further context on the totality of the substantial work that has been done. For example, the focus on LUAD and BRCA due to their representativeness could be supplemented by additional information on other cancers that may have been investigated similarly but where results were not presented due to lack of space.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101619.1.sa2</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The authors are trying to come up with a list of genes (GEAR genes) that are consistently associated with cancer patient survival based on TCGA database. A method named &quot;Multi-gradient Permutation Survival Analysis&quot; was created based on bootstrapping and gradually increasing the sample size of the analysis. Only the genes with consistent performance in this analysis process are chosen as potential candidates for further analyses.</p>
<p>Strengths:</p>
<p>The authors describe in detail their proposed method and the list of the chosen genes from the analysis. The scientific meaning and potential values of their findings are discussed in the context of published results in this field.</p>
<p>Weaknesses:</p>
<p>Some steps of the proposed method (especially the definition of survival analysis similarity (SAS) need further clarification or details since it would be difficult if anyone tries to reproduce the results. In addition, the multiplicity (a large number of p-values are generated) needs to be discussed and/or the potential inflation of false findings needs to be part of the manuscript.</p>
<p>If the authors can improve the clarity of the proposed method and there is no major mistake there, the proposed approach can be applied to other diseases (assuming TCGA type of data is available for them) to identify potential gene lists, based on which drug screening can be performed to identify potential target for development.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101619.1.sa1</article-id>
<title-group>
<article-title>Reviewer #3 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The authors describe a valuable method to find gene sets that may correlate with a patient's survival. This method employs iterative tests of significance across randomised samples with a range of proportions of the original dataset. Those genes that show significance across a range of samples are chosen. Based on these gene sets, hub genes are determined from similarity scores.</p>
<p>Strengths:</p>
<p>MEMORY allows them to assess the correlation between a gene and patient prognosis using any available transcriptomic dataset. They present several follow-on analyses and compare the gene sets found to previous studies.</p>
<p>Weaknesses:</p>
<p>Unfortunately, the authors have not included sufficient details for others to reproduce this work or use the MEMORY algorithm to find future gene sets, nor to take the gene findings presented forward to be validated or used for future hypotheses.</p>
</body>
</sub-article>
<sub-article id="sa4" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101619.1.sa0</article-id>
<title-group>
<article-title>Reviewer #4 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The authors apply what I gather is a novel methodology titled &quot;Multi-gradient Permutation Survival Analysis&quot; to identify genes that are robustly associated with prognosis (&quot;GEARs&quot;) using tumour expression data from 15 cancer types available in the TCGA. The resulting lists of GEARs are then interrogated for biological insights using a range of techniques including connectivity and gene enrichment analysis.</p>
<p>I reviewed this paper primarily from a statistical perspective. Evidently, an impressive amount of work has been conducted, and concisely summarised, and great effort has been undertaken to add layers of insight to the findings. I am no stranger to what an undertaking this would have been. My primary concern, however, is that the novel statistical procedure proposed, and applied to identify the gene lists, as far as I can tell offers no statistical error control or quantification. Consequently, we have no sense of what proportion of the highlighted GEAR genes and networks are likely to just be noise.</p>
<p>Major comments:</p>
<p>(1) The main methodology used to identify the GEAR genes, &quot;Multi-gradient Permutation Survival Analysis&quot; does not formally account for multiple testing and offers no formal error control. Meaning we are left with no understanding of what the family-wise (aka type 1) error rate is among the GEAR lists, nor the false discovery rate. I would generally recommend against the use of any feature selection methodology that does not provide some form of error quantification and/or control because otherwise we do not know if we are encouraging our colleagues and/or readers to put resources into lists of genes that contain more noise than not. There are numerous statistical techniques available these days that offer error control, including for lists of p-values from arbitrary sets of tests (see expansion on this and some review references below).</p>
<p>(2) Similarly, no formal significance measure was used to determine which of the strongest &quot;SAS&quot; connections to include as edges in the &quot;Core Survival Network&quot;.</p>
<p>(3) There is, as far as I could tell, no validation of any identified gene lists using an independent dataset external to the presently analysed TCGA data.</p>
<p>(4) There are quite a few places in the methods section where descriptions were not clear (e.g. elements of matrices referred to without defining what the columns and rows are), and I think it would be quite challenging to re-produce some aspects of the procedures as currently described (more detailed notes below).</p>
<p>(5) There is a general lack of statistical inference offered. For example, throughout the gene enrichment section of the results, I never saw it stated whether the pathways highlighted are enriched to a significant degree or not.</p>
</body>
</sub-article>
</article>